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ABSTRACT
Effect of Lactoferrin to increase drug permeability of primary pulmonary mycobacterial
granulomas
Thao Khanh Thanh Nguyen, B.A.
Advisory Professor: Jeffrey K. Actor, Ph.D.

Despite extensive research and worldwide eradication efforts, Mycobacterium
tuberculosis (Mtb) remains a major infectious pathogen to the human population with
about 10 million cases of infection per year globally. The host-pathogen interaction,
pulmonary granuloma formation, and Mtb adaptions result in increased complexity of the
disease. Granulomas are formed by active immune responses generated during Mtb
infection, and serve to contain and limit bacterial dissemination. The major mycobacterial
surface mycolic acid, trehalose 6,6'-dimycolate (TDM), functions in multiple ways to
enhance immune cell recruitment of sites of infection, to induce inflammation and
granulomatous responses, and to initiate survival strategies for the organism inside
macrophages. Mtb also benefits from establishment of a tightly formed granuloma, which
both protects it from immune reactivity and serves as a physical boundary to limit
penetration of drugs during therapeutic treatment. In order to demystify the complicated
relationship between the host and pathogen, many studies have been performed around
the primary Mtb-induced granuloma to combat the challenges that come with this specific
immunopathology. We hypothesized that by altering the immunopathology of granulomas
using lactoferrin, an immunomodulating agent, it will allow greater penetration of
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therapeutics into the site of focal inflammation. Our lab has reported that oral bovine
lactoferrin treatments during the innate immune response leads to significant modulation
of the primary Mtb granuloma response and lessen Mtb burden in mouse lungs. Here, we
show that such modulation during granuloma development can also be achieved by using
recombinant human lactoferrin oral treatments to increase granuloma permeability and
promotes drug penetration in both TDM-induced granulomatous inflammation as well as
during active Mtb-infection. Findings from this work show lactoferrin’s potential as a hostdirected therapeutic that can be combined with current TB standard treatment to reduce
pathological damage in the lungs post mycobacterial infection.
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CHAPTER 1: INTRODUCTION

Tuberculosis disease as an epidemic

It has been over a century since Robert Koch identified the etiological agent of
human tuberculosis (TB) [2, 3]. However, to date, this pathogen continues to be a problem
for human health. As a single infectious pathogen, Mycobacterium tuberculosis (Mtb) is one
of the top 10 causes of death in middle to low-income countries [4]. In 2020, the Centers for
Disease Control and Prevention estimated a fourth of the world’s population is infected
with TB, with more than 500,000 cases of multidrug-resistant TB reported each year. In the
United States alone, about 13 million people currently have latent TB. They show no
symptoms of the disease, but have the risk of reactivated infection later in life [5].

Mtb is transmitted between individuals in close proximity by inhalation of Mtbcontaining droplets from a Mtb infected person following coughing, sneezing, or forced
respiratory activities [6]. Though most people with latent TB will not develop TB disease in
their lifetime, immune compromised individuals, such as HIV-positive people, are at the
highest risk to develop active TB infection from the latent TB state [7]. According to the
American Lung Association [8], active TB symptoms include, but are not limited to, a
persistent coughs that lasts more than three weeks, weight loss, fever, chills, and night
sweats. More severe symptoms are fatigue, hemoptysis (coughing up blood), bone pain,
and shortness of breath. There are four first-line antimicrobials drugs used in standard TB
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treatment regimen: isoniazid, rifampicin, pyrazinamide and ethambutol [9]. Treatment for
TB lasts much more than other bacterial infections and takes 180 days of medication in
average [5]. However, some Mtb strains can display three different types of phenotypic
resistance to antibiotics. The first and most familiar is genetic resistance – some Mtb strains
now possess mutations that produce resistance phenotypes to particular drugs, which is
now the biggest threat to human as they continue to evolve while we exhaust our
treatment options. The second is when resistance occurs as Mtb become dormant, resulting
in their refractory to agents that inhibit active metabolic processes. Finally, there is also
natural resistance consists of physical barriers and efflux pumps that reject the penetration
of antibiotics into these bacteria [6, 10].

Despite extensive research and available low-cost treatments for most Mtb strains,
Mtb remains a major public health threat. Recent forward progress in slowing spread of
disease was heavily reversed due to the current Covid-19 pandemic. Currently,
approximately 10.0 million active cases and 1.5 million deaths due to Mtb were reported in
2020 globally [11]. As SARS-CoV-2 became a more urgent threat to global health, essential
resources such as diagnostic equipment, staff, relocation of social care budgets, and even
hospital beds were allocated to Covid-19 treatment and inpatient care. Pandemic related
lockdowns prevented early diagnostic identification of Mtb infection spread, and social
distancing guidelines disturbed on-time treatment schedules for Mtb patients. Therefore,
eradicating efforts are significantly delayed due to the drastic effect on health and society
of Covid-19 since early 2020, with world-wide Mtb detection efforts have been obstructed
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heavily, with WHO’s predictions of a 0.2–0.4 million decrease in number of infected
individuals receiving treatment by the end of 2020 [11].

Tuberculosis Disease

Mtb was identified in the 1880’s through a series of experimental works by Robert
Koch as the source for cavitary disease that can lead to chronic lung disorder in human [2].
Tuberculosis manifests disease in two clinical stages [12-14]. The initial stage (primary
infection) is readily controlled by individuals with competent immune function. In fact, the
majority of individuals exposed to Mtb are able to contain and control infection in a matter
of weeks without extreme clinical pathology. The primary infection is relatively contained,
with a loosely structured granulomatous nodule comprised of central macrophages and
surrounding adaptive cells. Most clinical disease is that which is seen during post-primary
stages of infection. In this case, re-infection (or reactivation of latent organisms) by Mtb
induces a pneumonia exudative reaction that can progress to a necrotic lesion [15]. This
lesion is hypothesized to be controlled by strong and directed adaptive immune reactivity
[16]. The other type of pathology is a relatively contained walled-off nodular tubercle, or
caseating granuloma, where organisms may reside and induce continued immune
responsiveness [16, 17]. What sets Mtb away from other bacterial infections is its silent
attack on the human body resulting in granuloma contained organisms in the majority of
post-primary infected people, in which they do not display clinical symptoms but still carry
either persistent bacteria or strong immune reactivity that reflects on the positive TB skin
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test [18-20]. It is easy to imagine a state of latency in which the risk of reactivation, of postprimary Mtb infection, later in life due to weakened immune system that fails to continue
inhibiting the growth of latent bacilli. Such latent (post-primary) infection causes the
majority of TB cases and most of the bacilli transmission [21]. Histologically, post-primary TB
is characterized as a lipid pneumonia with foamy macrophages and mostly CD4+
lymphocytes present in the alveoli. A pathological effect is seen when lung tissue ruptures,
hypothesized as due to immune reactivity towards an accumulation of mycobacterial
mycolic acid antigens [22]. Clinically, this coincides with observed caseating granulomas.
Such pulmonary cavitary lesions causes shortness of breath, fatigue, and permanent tissue
damages. Immune responses, likely originating from pneumonia, lead to destruction of
bronchial passages; subsequent and coughing produces infectious aerosols that can infect a
new host [17, 21, 23, 24].

Tuberculosis model – The TDM Granuloma

Much of our observation of disease pathology in humans comes from autopsy of
lung disease where pneumonia and caseating granulomas both occur. While the true
establishment of mechanisms involved in post-primary infection are still under
investigation, it is clear that the granuloma plays a major role in containment of organisms.
Our laboratory understood the need to investigate early innate responses that control initial
processes during infection. Hence, the study of primary infection relied on the
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establishment of animal experimental models which permitted direct investigation into
early events that induce the containment response during initial infection.

It is essential to study the disease in an animal model that can mimic the primary
signature granulomatous response to Mtb. Early experiments identified a cell wall
associated component that was a major factor responsible for the interaction between
organisms forming the serpentine cords [24, 25]. This “factor” was later identified as
Trehalose 6,6’-dimycolate (TDM), which has been confirmed as the most abundant
component of the lipid-rich mycobacterial cell wall. Experimentally, TDM was found to be a
useful molecular tool to mimic the primary granulomatous response seen in Mtb infection
[26]. Now known as the main mycolic acid of the outer layer of the organism, TDM has been
studied for many decades and further identified as the most prevalent virulence factor of
Mtb that induces immune pathogenesis. The mouse is an accepted and appropriate animal
model system to study how cord factor/TDM initiates the primary granulomatous pathology
induce in lung tissue.

Another major property of TDM is that it is known to alter the local
microenvironment within macrophages to assist in organism survival [25, 27]. TDM plays a
crucial role in Mtb survival; when removed from the organisms, their ability to survive in
macrophages is significantly decreased and can be restored when purified TDM is
reintroduced [28-30]. Furthermore, TDM has been shown to contribute significantly to the
virulence of Mtb by reducing phagosome acidification and fusion with lysosomes. TDM can
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also alter the expression of antigen presenting and T-cell activating markers of macrophages
such as MHC II, CD40, CD80, and CD86 [30, 31].

TDM’s virulent and toxic properties lie within its unique structure. The molecule
consists of two trehalose molecules with a long mycolic acid chain of 50-60 carbons, with an
extended alpha-carbon branch, that binds to each trehalose molecule. The unique “kinks” in
the carbon chains are hypothesized to be responsible for its rigidity and biological activities
in a way that allows TDM to be toxic or non-toxic, depending on its presentation [32, 33].
Elimination of this “kink” affects organism virulence [34, 35]. TDM is non-toxic when it is in
the form of micelles due to its hydrophobic tails in an aqueous solution, but becomes toxic
when forms a monolayer on hydrophobic surfaces. When it is given as an oil-based
emulsion that produces roughly 1.0 m droplets, purified TDM alone can induce innate
immune response within the lung tissues where pro-inflammatory cytokines and chemokine
productions are increased and immune cells are recruited to establish primary granulomas
that mimics primary Mtb infection [36]. Hence, its application in producing primaryinfection like pathology in murine lungs has been utilized in studies of primary Mtb infection
and granulomas formation [37].

Innate Immune Response to Mtb in Mouse Model

Development of Mtb animal models have allowed generations of scientists to
investigate Mtb primary infection despite the lack of untreated human specimens. Multiple
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animal species have been instrumental to investigate Mtb pathology [25-30]. For simplicity,
this introduction will specifically focus on infections within the mouse model which was
used for all parts of this study. Overall, Mtb primary infects the lungs and causes major
disruption to lung pathology by inducing inflammation structures called granulomas [31,
32]. Granuloma development is the hallmark of Mtb infection and plays an essential role in
both bacterial containment and symptom development [33]. During primary Mtb infection
in the mouse, Mtb associated factors are involved in the recognition and activation of host
cells within the bronchial regions and alveolar sacs, leading to uptake by alveolar
macrophages [32, 34]. This interaction triggers a series of immune responses initiated via
the production and release of cytokines by infected and responding macrophages [35-38].
For example, TDM, an abundant mycobacterial mycolic acid as introduced earlier, is
recognized by Mincle (macrophage-inducible C-type lectin) on the macrophage surface
driving M. tuberculosis -host recognition [39], which significantly initiates the
granulomatous response [21]. Activated macrophages subsequently release proinflammatory mediators, such as TNF-α and IL-1β [37], along with additional chemotactic
factors to further recruit immune cells to areas of infection [36, 40, 41]. Over time,
additional recruited immune cells, such as foamy macrophages, epithelioid cells, and
Langhan’s giant cells, participate in formation of organized, sphere-shaped primary
inflammatory structures at the infected site called granulomas [31, 42]. Disease
development can happen even during robust immune response so that, although
successfully limit the infection within the granuloma [33], allows bacteria to survive and
grow within the infected macrophages [43]. This happens because of various reasons: Mtb
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have adopted mechanisms to survive within macrophages by persisting without causing
inflammation [44], preventing phagolysosome fusion [45, 46], recruited naive macrophages
during the immune response can become new potential sites for Mtb to shelter and
replicate [47], and the dense physical nature of the granuloma limits the penetration of
anti-mycobacterial chemotherapy [48, 49]. These factors can lead to the bacterial survival,
challenges in treatment efforts, and increase the risk of latent Mtb infection. It is believed
that mature granulomas is the balance between the arrest of organisms to proliferate due
to sufficient adaptive immunity [50] and the survival of intracellular Mtb despite killing
mechanisms [43, 51].

Macrophages

As a major factor of the innate immunity, macrophages possess mechanisms that
allow it to control Mtb proliferation. Once activated, macrophages exercise cytotoxic effects
that produces nitric oxide (NO) and reactive nitrogen intermediates, which have been
shown both in vitro and in vivo to be important for protection against Mtb [52-54]. As an
antigen-presenting cell, macrophages also play a key role in presenting digested Mtb
antigens and produce IL-12 for the initiation of adaptive immune response by lymphocytes
[55, 56].

Despite its ability to eliminate Mtb, macrophages also contribute to the persistent
nature of Mtb. Alveolar macrophages play the crucial role of recognizing and phagocytosing

8

Mtb when first encounter them in the alveoli using mannose receptors, complement
receptors, and scavenger receptors [57-59]. Typically, the phagosome then undergoes
maturation processes and fuses with lysosome to kill and break down bacteria with
organelle acidification and activated lytic enzymes. However, Mtb has adapted to survive
within the phagosome by using TDM to prevent the phagolysosomal fusion, which allows it
to hide within macrophages from other immune factors and even chemotherapies [45, 46,
52].

It has been recently discovered that macrophages can polarize towards the
classically activated (M1) or the alternatively activated macrophages (M2). Macrophage
polarization is stimulated by the microenvironment surrounding naïve macrophages [60].
M1 macrophages are induced by cytokines such as IFN- and TNF-α, and bacterial antigens
such as lipopolysaccharide (LPS). Once committing to the M1 phenotype, macrophages
produce more pro-inflammatory cytokines such as IFN-, TNF-α, and IL-1β, and other
molecules important for cytotoxic effects such as reactive oxygen species (ROS) and
inducible nitric oxide synthase (iNOS). On the other hand, cytokines such as IL-4, IL-10, and
IL-13 can induce M2 polarization in macrophages, resulting in production of antiinflammatory cytokines such as IL-10 and TGF-β responsible for immune-regulatory and
tissue-remodeling [61-63]. In mice, markers for murine M1 macrophages are identified as
high expression of CD38 (T-cell receptor) and CD86 (transmembrane protein that both
activates and inhibits T-cells), and M2 macrophages have high levels of CD206 (mannose
receptor) and EGR2 (transcription factor) [64, 65]. Macrophage populations from Mtb

9

infected mouse lungs show plasticity of response over time [60, 66]. Though it has only
been investigated recently, evidence shows that the macrophage polarization is closely
related to the pathogenesis of Mtb infection and chronic obstructive pulmonary disease. In
TB mouse models, the early stages of infection and granuloma establishment are marked
with high level of M1 macrophages detected up to 30 days post-infection, while M2
macrophages levels are increased towards the middle and later phases when inflammation
is resolved [67-69].

Host-directed therapy in Mtb treatment

As mentioned above, it has been established that Mtb can manipulate the immune
system to favor its survival at the molecular level [70]. Its adaptation to survive within
macrophages after phagocytosis [44-46], an immune cell population that was meant to
engulf and digest foreign organisms, was only one piece of the puzzle. Studies have shown
that Mtb virulence factor alone, TDM, can increase macrophage recruitment to the infected
sites for new “hiding” opportunities [47] and induces host cell apoptosis [71]. Mtb can also
delay the adaptive immune response by limiting stimulated dendritic cells’ migration from
alveolar spaces in the lungs to lymph nodes, which slows down the initial T-cell activation
[72-74]. Therefore, adjunctive treatments aimed at redirecting the immune system are
critical alternative approaches to counteract Mtb manipulative strategies [75].
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Due to the pathological damage and therapeutic challenges caused by Mtb
adaptation to its survival within granulomas, researchers have been investigating
immunotherapy approaches that can improve lung pathology and increase drug penetration
to fight hiding bacteria inside granulomas. Novel approaches to Mtb treatment include
host-directed therapy [75, 76] which focuses on two major fronts; the first sharpens
immune response, such as immune-based treatments [77], while the second alters the
resultant immunopathology [78]. An example of immune-based treatments includes agents
that target the macroautophagic compartment, such as vitamin D and retinoic acid which
increase phagocytosis and augment the lysosomal degradative process to increase Mtb
removal inside macrophages [79]. Ibuprofen, an anti-inflammatory drug, also showed its
potential as an adjunct treatment for Mtb infection by enhancing mycobactericidal effect of
pyrazinamide and alleviate pathological damage in the lungs [77, 80, 81]. These immunebased approaches have significant potential, demonstrating superior disease outcomes in
mouse models. However, these approaches face many challenges such as conflicting clinical
trial results [82, 83] and drug delivery to macrophages inside established granulomas [84].

On the other hand, therapies that target pathologies are also valid as potential
clinical candidates. A well-known example of the immunopathological alteration approach is
blocking excess TNF-α, a key pro-inflammatory cytokine required for granuloma formation
and proper recruitment of immune cells to form granulomas, to reduce lung pathological
damage. TNF-α inhibitors have been used to treat other inflammatory diseases effectively
[85-87]. However, its major disadvantage is the increased risk of bacterial dissemination;
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abolishing the granuloma containment modality runs the risk of Mtb reactivation [88-91].
Another example of the second approach is granuloma modulation by lactoferrin [92].
Lactoferrin, a glycoprotein known for its ability to bind iron, has been extensively studied
for its role as an immune modulator in host defense in infected patients and disease
models; lactoferrin has been shown to boost immune memory response in vaccine models,
while reducing pro-inflammatory response in LPS-exposed mouse models [93-97]. In recent
years, research has shown significant modulation of the Mtb primary granuloma response
using lactoferrin treatments. Bovine lactoferrin significantlly reduced inflammatory
pathology in TB-infected mice [98]. Human lactoferrin was also shown effective to limit
inflammation in the non-infectious TDM-induce granuloma mouse model [78, 99].

Lactoferrin as a therapeutic approach to TB treatment

Lactoferrin is a single polypeptide chain glycoprotein that consists of about 690
amino acid residues and folds into two globular structures consisting of iron binding sites
[100, 101]. It was found primarily as a glycoprotein produced by epithelial cells in mucosal
secretions but is also made and stored in neutrophilic granules functioning as an innate
immune response component [102]. Overall, lactoferrin has been shown to involve in
protection during multiple microbial infections and prevention of systemic inflammation
[97, 103-107]. Lactoferrin’s biological functions during infections are known as three main
effects: first is the bacteriostatic effect by removing the iron supply from environment to
slow down bacterial growth, second is the bactericidal effect due to lactoferrin’s affinity to
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bacterial lipopolysaccharides (LPS) in Gram-negative organisms, and third is the immune
modulating effect where it can either boost or downregulate the immune response
depending on the current immune status [108-116]. As preventive measures, lactoferrin
can also prevent infection by inhibiting binding of pathogens with receptors used for entry
on host cells [117-119] and boost immune memory response in vaccine models [94, 95].

Known as an immune modulator, lactoferrin can affect the immune response by
modulating several immune cells’ functions. During innate immune response, lactoferrin
can reduce the production of proinflammatory cytokines produced by activated or infected
macrophages such as TNF-α, IL-6, and IL-1β [78, 115, 120] and enhance phagocytic activity
of macrophages [120, 121]. Similarly, lactoferrin has been shown to reduce production of
stimulation-induced cytokines such as TNF-α, IL-12, and IL-1β in dendritic cells – another key
antigen presenting cell population during innate immune response [122, 123]. As infection
progresses and leads to the adaptive immune response, lactoferrin has been shown to
increase surface expression of CD40 and IL-12 production of macrophages, which are key
co-stimulatory factors responsible for activating T-cells and increasing secretion of IFN-γ
from T-cells respectively, at the sites of infection [124-126]. In different infectious disease
models, lactoferrin can either favored a T-helper 2 response [127, 128] or increase the Thelper 1 response [129]. In murine B-cells, lactoferrin can also promote maturation of Bcells and increase their ability to promote antigen-specific T-cell proliferation [130]. These
immune modulating effects are the results of lactoferrin binding to different receptors on
immune cells; other than binding to lactoferrin receptor (LfR), which are found on the
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surface of monocytes, T-cells, and B-cells [131-134], lactoferrin can also interact with a
variety of cell surface receptors such as Toll-like receptor 4 (TLR4) and CD14 on
macrophages, and CD22 on mature B-cells [135].

In the case of host anti-Mtb response, previous studies have shown its modulating
effect during primary infection by reducing proinflammatory response that is responsible
for pathological damage in the lung tissues. Latest primary granuloma models show that
bovine lactoferrin significantlly reduced inflammatory pathology in TB-infected mice [98]
and human lactoferrin can similarly limit inflammation and granuloma size in the noninfectious TDM-induce granuloma mouse model [78, 99]. Such anti-inflammatory response
in the lactoferrin-treated mice, along with other data showing lactoferrin reduced proinflammatory phenotypes in macrophages [136, 137], suggests that lactoferrin had a
modulating pro-inflammatory response on granulomas. This thesis extended theses
observations to examine if recombinant-human lactoferrin can modulate granulomatous
pathology and its permeability, and if we can utilize such effect to increase drug distribution
during innate immune response or granuloma formation. The effect of lactoferrin on the
permeability of granulomas to fluoroquinolones is examined in both TDM-challenged and
Mtb-infected mouse model, while administered as a prophylactic (prior to granuloma
formation) or therapeutic (after granuloma establishment) intervention during primary Mtb
infection. In addition, effects of lactoferrin treatment on the expression of M1/M2
phenotypes as well as endothelial-lined vessel structures are examined within the
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granuloma, shedding more light into the potential mechanisms behind the pathological and
drug distribution changes.

Summary of Thesis

This thesis explores how macrophages polarize during primary granuloma
development and how lactoferrin, as an immune modulator, alters pathogenesis of primary
infection in a way that makes increased drug distribution within granulomatous structures a
possibility. The first study verified macrophage polarization into M1 phenotype during the
innate immune response in the TDM-induced model of primary Mtb granulomatous
response (Chapter 2). Once the model is validated, the second study investigated the effect
of lactoferrin to alter drug permeability of primary pulmonary mycobacterial-like
granulomas (Chapter 3). Mtb infection is a very complex disease that progresses due to
both bacterial growth and persistent immune response. Therefore, the effect of lactoferrin
to alter drug permeability of primary granulomas was evaluated in the last study by giving
Mtb-infected mice lactoferrin prophylactically and therapeutically, as a proof of concept to
explore potential differences in effectiveness of each intervention timing (Chapter 4).
Finally, the effects of lactoferrin and its immune-modulating mechanisms, as well as future
directions, are discussed in Chapter 5.
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CHAPTER 2: MYCOBACTERIAL TREHALOSE 6,6’-DIMYCOLATE INDUCED M1-TYPE
INFLAMMATION

This work is reprinted from The American Journal of Pathology, Volume 190, Issue 2,Thao K T
Nguyen, John d'Aigle, Luis Chinea, Zainab Niaz, Robert L Hunter, Shen-An Hwang, Jeffrey K
Actor, Mycobacterial Trehalose 6,6'-Dimycolate-Induced M1-Type Inflammation, Page 286394, Copyright (2019), with permission from Elsevier.
(https://doi.org/10.1016/j.ajpath.2019.10.006)

Introduction

Dogma in tuberculosis pathology is the notion that induction of a strong T-helper 1
lymphocyte (Th1) phenotype is critical in maintaining protective health during primary
mycobacterial infection [138, 139]. Development of this phenotypic outcome is based on
critical aspects of the macrophage and its initial interactions with the infectious organism
[140-142]. Multiple organism-induced mechanisms have been identified that function to
evade host responses [143, 144], essentially limiting effectiveness of this avenue of Th1
lymphocyte response. Many of these evasive properties directly affect macrophage
functions [145]. The relatively recent realization that macrophage populations can be
subdivided into pro- and anti-inflammatory subsets has sparked a revolution in
understanding the complexities of innate responding cells to subsequent immune
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outcomes; this has important consequences on ensuing granuloma pathologies post
infection [146-148].

The primary stages of mycobacterial infection manifest with a robust proinflammatory response in order to effectively mitigate organism dissemination. Indeed,
these host responses induce hemorrhagic inflammation and vascular occlusion [149, 150],
that coincide with changes to fibrinolytic activity and thrombosis [151], which are in many
ways beneficial for limiting spread of microorganisms. Certainly, the establishment of a
granuloma is considered protective [43, 152], even though it provides a specialized niche
within the lung for organisms to replicate.

A major molecule influencing acute reactivity upon entry of Mtb into the host is the
mycobacterial cord factor component trehalose-6,6’-dimycolate (TDM). Multiple models of
the TDM-induced pulmonary granulomatous response have been studied in mice, all of
which have common features to those identified in early acute primary immunopathology
of the human host. Initially, Block and Noll (1955) utilized cord factor to mimic pathologies
seen in early primary human disease [153], including changes to fibrinolytic activity [149,
150] and thrombosis [151]. Perez, et al., successfully repeated these experiments using
purified TDM [154]; Donnachie, et al. [155], and Hwang, et al. [156], built on this using
molecular tools to further examine early events in extravascular coagulation. Alternate
models of the primary TB response were developed using administered TDM to initiate a
synchronized transient granulomatous response [157-159]; these models are extremely
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effective to assess monocyte-macrophage factors involved in primary granuloma
pathogenesis. Indeed, modifications to this model have allowed further insights into how
macrophages utilize required receptors to initiate the cytokine cascades [160], and how
these events can push the macrophages to elicit hypersensitive responses [161, 162].

The common link between the different models is the relatively rapid initiated proinflammatory macrophage responses elicited in vivo by TDM. Here, we desired to further
examine the nature of the macrophage phenotype response to TDM, and determine the
histopathological evidence to support a hypothesis linking TDM to the presence of recruited
macrophage polarization to an M1-like phenotype. Evidence presented in this report uses
histologic markers and flow cytometry, immunostaining, and ELISA methods to link TDM as
a driver for the M1-like macrophage phenotype during recruited induction of the primary
granulomatous pathology.

Materials and Methods

Mice. Female C57BL/6 mice (Envigo, Houston, TX) were five to six weeks of age, and
approximately 20g weight, at study initiation. Animal work was performed at the University
of Texas Health Science Center (UTHSC) animal welfare committee, according to protocols
detailed in approved documents HSC-AWC-16-0140 and HSC-AWC-17-0089.
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TDM Induced Lung Pathology. Mycobacterial-derived TDM (cord factor) (Enzo Life
Sciences, Farmingdale, NY) was solubilized in hexane:ethanol, at a ratio of 9:1. Material was
evaporated by a stream of air. The TDM oil/water emulsion was prepared as previously
described [159]. Briefly, evaporated TDM (25 g/mouse) was homogenized in Drakeol (2
l/mouse) (Penreco, Indianapolis, IN). Then 48 l/mouse of DPBS 1x (Dulbeccos’ Phosphate
Buffered Solution, Cellgro) with 0.2% Tween-80 (Mallinckrodt, Hazelwood, MO) was added;
the mixture was homongenized in a glass tube and Teflon pestle for 1 minute to produce an
oil/water emulsion. The TDM was intravenously (IV) given at a volume of 100 l per animal.
Control mice received material formulated with no addition of TDM in oil. Emulsion only
controls did not exhibit inflammation, nor did they exhibit cytokines production, at the
times described here, as was previously reported and detailed [158, 163]. All mice were
sacrificed at times indicated (7 days after injection of formulated material.

Histological Assessment. Mice were sacrificed, and lungs were immediately perfused
with a solution of 1mM EDTA in DPBS. Lungs were weighed, sectioned, and evaluated for
pathology and histological results. Tissues were fixed in 10% buffered formalin for histology
(Fisher Scientific, Pittsburg, PA). Specimens were processed by the Histology Laboratory at
the UTHSC McGovern Medical School (Houston, TX); tissues were embedded in paraffin
blocks and then 5 μm thick sections were subsequently stained with hematoxylin
(Surgipath, Richmond, IL) and eosin (Richard-Allen Scientific, Kalamazoo, MI).
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Lung weight index (LWI). Our laboratory utilizes an accepted lung weight index (LWI)
which calculates as an approximation of lung inflammation intensity. The following
equation was used for calculation of the gross tissue inflammation due to TDM induced
pathology, as used in prior studies [158, 164, 165]:

Lung weight (g) x 1000

LWI =

Mouse weight (g) / 10
10

Computerized analysis. High resolution scanned images of H&E-stained slides were
scanned for computerized analysis of lung inflammation using Motic DSAssistant software
(Kowloon Bay, Kowloon, HK). Quantitation of inflammation was performed in two steps
using ImageJ (Version 1.52o 23 April 2019, National Institutes of Health, Bethesda, MD).
Lung area was initially quantified by separation of the image’s scale from background.
Minimum and maximum values for hue, saturation, and brightness of the image were set as
follows: 120, 255; 0, 255; and 0, 255, respectively. Total cell area measurement was
calculated using a modified version of the procedure detailed in the online ImageJ stainedsections example directory (https://imagej.nih.gov/ij/docs/examples/stainedsections/index.html; version 1.52a), where peak threshold was set at 164 for all digitized
slides analyzed. Methods were similar to published materials [166]. Lung inflammation was
calculated as a percentage of total area occupied by cell area; values were averaged within
treatment groups and normalized to that of group non-treated controls.
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Lung cytokine production. A weighed section of lung was excised, then
homogenized, then incubated at 37oC and 5% CO2 for 4 hours in Dulbecco’s Modified
Eagle’s medium (DMEM) containing 50 μg/ml L-Arginine, 50 μg/ml HEPES, 100 μg/ml
penicillin, and 50 μg/ml gentamycin, and 10% fetal bovine serum. Collected supernatants
were spun to remove debris, then assessed by enzyme-linked immunoassay (ELISA).
Production of TNF-α, IL-1β, IL-12p40, IL-6, TGF-β and IL-10 was determined by
manufacturer’s instructions (DuoSet kits, R&D Systems, Minneapolis, MN). Supernatants to
detect TGF-β were pretreated with 1:5 ratio of 1N HCl, then neutralized with same volume
1.2N NaOH/0.5M HEPES. The average of duplicate wells was determined using a standard
curve produced by reactivity to manufacturer’s supplied recombinant molecules. Detection
sensitivity limit was at least 32 pg/ml, according to manufacturer product details.

Immunohistochemical analysis. The large right lobe of each lung was collected and
fixed in 10% buffered formalin. The fixed lung tissue was stained with hematoxylin and
eosin (H & E) using standard procedures. Assessment was performed using
immunohistochemistry for integrin family member CD11b (Absolute Antibody, Cat#
Ab01114-23.0; Wilton, UK) [167], diluted at 1:2000, was performed according to
modification of manufacturer’s instructions (20 minutes at low pH), and subsequently
visualized using standard HRP techniques and DAB chromogen using Dako reagents (Dako,
Agilent, Santa Clara, CA). In a similar manner, M1-like marker CD38 (Invitrogen,
ThermoFisher, Cat# 14-0381-02), diluted at 1:1000, was used for visualization on serial slide
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sections. Henatoxylin counterstained slides were viewed by a trained pathologist, with
descriptive results obtained in an experimentally blinded manner.

Flow Cytometry Analysis. Lungs were extracted from WT and TDM treat,
homogenized by hand, and underwent a 30-minute Collagenase/Hyaluronidase (StemCell
Technologies) and DNAse I (Sigma) incubation in sterile filtered RPMI-1640 with 1% 100X
pen/strep and 2.5% HEPES (Thermo Fisher Scientific), and 5% HI FBS 9Corning). Enzymatic
digestion was quenched with addition of RPMI mixture before lung tissue was plunged
through a 70-micron cell strainer. Cells were pelleted at 4C for 5 minutes at 450rcf (g). Cell
pellets were re-suspended in a 70% GE Healthcare Percoll (Cat# 17-0891-01) gradient and
underlaid in 40% Percoll followed by a 20-minute 22C 500rcf centrifugation with no break
and slow acceleration. Cells were collected at the 70-40 Percoll interface before being resuspended in sterile filtered PBS mixture containing 2% HI FBS and 1mL of 0.5M EDTA
(Thermo Fisher Scientific). Surface markers chosen to delineate murine M1-like and M2-like
macrophages were based on published data from Jablonski, et al., [65], later detailed by
Orecchioni, et al. [168]. Similar findings were identified in human monocyte-derived
macrophages [169].Cells were stained in accordance with manufacture recommendation,
using Live Dead Aqua (eBioscience, L34966) for 15 minutes, then FC (antibody receptor)
blocked with Anti-Mo CD16/CD32 (eBioscience, 14-0161-86) for 15 minutes. Staining used
the following antibodies against specific receptors: CD38 (Biolegend, Cat# 102728) APC/Cy7,
CD86 (Biolegend, Cat# 105014) PE/Cy7, CD206 (Biolegend, Cat # 141704) FITC, EGR2
(eBioscience, 17-6691-82) APC, CD11b (Biolegend, Cat# 101208) PE, and CD45 (eBioscience,
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48-0451-82) eFluor 450 for 20 minutes. Cells were fixed with 2% paraformaldehyde, and
evaluated on a Beckmen Coulter Cytoflex S flow cytometer (Model No. B75442). Data was
then analyzed using FlowJo V10 (Becton Dickinson).

Statistical Analysis. Collected data was compared across groups, and against naive
mice or mice challenged with vehicle formulated without TDM. Analysis used an unpaired ttest, or used one-way ANOVA. The differences between means were considered significant
at a level of p≤0.05. Generated data points were compiled using GraphPad Prism (San
Diego, CA) and are presented as a representative value obtained from multiple
experimental repeats (sets of 2 or 3). Experiments had an N of 4 to 6 mice.

Results

TDM Induced Pathology: Acute Granulomatous Response.
C57BL/6 mice injected with Mtb derived TDM (25 g/mouse) in oil/water given
intravenously developed inflammation in lung tissue of (Figure 1). Broad lung inflammation
was assessed as lung weight index (LWI) at 7 days after IV TDM challenge; This time point
reflects peak granulomatous response induced by TDM [158]. Acute treatment increased
LWI significantly. TDM treated mice had an average LWI of 1.60 +/- 0.49 units, compared to
naïve controls (0.97 +/- 0.03 units; p≤0.05). The LWI was similar to computerized
assessments of lung inflammation. Analysis of digitized lung histograms post TDM
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administration confirmed significant parenchymal inflammation and presence of
granulomas throughout pulmonary tissue.
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Figure 1. Comparative Gross Pulmonary Inflammation during TDM Induced Pathology.
Lungs from mice given TDM (25 g; IV) were assessed after 7 days and compared to control
naïve mice. The lung weight index (A) was calculated to quantify gross pulmonary
inflammation. Digital analysis of area occupied due to cellularity (B) confirms induction of
inflammatory response. Results represent mean ± standard error of the mean (SEM). Similar
data was obtained in 3 repeated experiments; 4-6 mice were included per group, per
experiment. *; p≤0.05. Histologic examination of lungs at day 7 post TDM administration
revealed acute granulomatous response culminating in high levels of monocytic infiltration,
with increased presence of focal macrophages (D), versus non-TDM treated control mouse
lungs (C). Higher magnification reveals “foamy” vesiculated macrophages aggregating
between regions of relatively normal parenchyma. Formalin fixed lung sections were
hematoxylin and eosin stained (H&E); histopathology shown at 10x magnification; inset at
40x, scale bar = 300m. Sections represent data obtained from repeated experiments. 4-6
mice were in each group, per experiment.
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Histological Assessment of TDM Induced Pathology.
Mice administered TDM IV showed a focal accumulation of macrophages at day 7
post injection (Figure 1). The pathological reactivity demonstrated widespread
inflammation and severely reduced open alveolar space. Small focal hemorrhagic petechiae
were present as part of the inflammatory response. Lymphocytic infiltration to lung tissue
occurred around regions where granulomas coincided with vasculature. Slight hemorrhage
was present throughout the tissue. There was visual evidence of occlusion of intermediate
or small sized blood vessels. Activated macrophages with intracellular vesicles were
predominant in regions of reactivity; limited to negligible accumulation of lymphocytes
occurred within the focal response. General edema was not a major component of the
response. Naïve (no TDM) mice did not demonstrate changes to lung architecture. Lungs
from control mice exhibited normal pulmonary parenchyma; there were no noticeable
cellular infiltrates, and limited presence of monocytic or leukocytic foci.

Pro-inflammatory Response in Pulmonary Tissue of TDM Treated Mice.
It was previously reported that administration of TDM results in a strong proinflammatory response [159]. Cytokine assessment was assessed by ELISA to confirm these
findings. Lungs were examined at 7 days post administration of TDM. Significant production
of pro-inflammatory mediators TNF-α, IL-1β, and IL-12p40 were observed relative to control
mice; IL-6 was also elevated in the TDM treated group (Figure 2). Anti-inflammatory
mediating cytokines were also evaluated; while there was minor increase in production of
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TGF-β, it was not a significant change. There was no change, relative to controls, in IL-10
production (Figure 2).
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Figure 2. Pro- and Anti-inflammatory Cytokine Mediators in Lung Tissue during TDMInduced Response. ELISA assessment of inflammatory cytokines revealed increase in
production of TNF-α, IL-1β, IL-12p40 and IL-6 at day 7 post administration of TDM,
compared to non-TDM treated control mice. Lungs of mice receiving TDM did not reveal
significant changes in production of TGF-β and IL-10. Results represent mean ± SEM,
representative data was collected from 3 independent experiments in which 4-6 mice were
in each group per experiment. *; p≤0.05.
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Identification of the M1-like Macrophage Phenotype within Regions of TDM Granulomas.
The extent of macrophage phenotypic polarization was investigated using flow
cytometry. Lungs treated with TDM were dissociated, and individual cells were further
examined for presence of M1-like and M2-like surface markers. Populations were initially
gated on infiltrating monocytic macrophages (CD11bhiCD45hi) [170, 171]. Figure 3 depicts
data collected for M1-like markers CD38 and CD86, along with assessment for expression of
the M2-like markers CD206 and the early growth response gene-2 (EGR-2). Treatment with
TDM resulted in an overall accumulation of CD11bhiCD45hi cells that expressed higher M1like markers, but not the M2-like surface proteins. Specifically, CD38 was present on 39.50%
+/- 3.33% on infiltrating macrophages, which was significantly elevated when compared to
the non-treated WT group controls (7.76% +/- 2.24%; p≤0.001). Additionally, CD86 was
present on 19.34% +/- 1.48% macrophages, compared to non-treated controls (5.31% +/0.61%; p≤0.001). Figure 3 also lists the values for markers examined. CD14 was also highly
elevated in this population (57.74% +/- 4.06%; data not shown).
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Figure 3. Flow Cytometry Assessment of M1/M2-like Markers on Infiltrating MonocyteMacrophages. Isolated cells obtained from lungs at 7 days post administration of TDM were
examined by flow cytometry for expression of M1-like markers CD38 and CD86 (top), and
for M2-like markers CD206 and EGR-2 (bottom). Isolated cells were first gated to identify
CD11bhiCD45hi macrophages, then further analyzed for surface expression; Representative
histographic plots of data accompany dot plots, side scatter (SSC) shown vs. signal intensity,
for TDM treated (blue) or wild type (WT) controls (orange). Analysis on right indicates
average (Avg) percent values with standard deviation (STDev) for each marker indicated
from 4-6 mice. One Way ANOVA, p≤0.05, Tukey Post Hoc test for multiple comparisons:
**p≤0.001 for CD86 TDM vs wild type.
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Immunohistochemical staining allowed localization of the CD11b+ macrophage
population to regions of granulomatous response (Figure 4A), and specifically to areas of
inflammation. Furthermore, staining for the CD38 surface glycoprotein marker on serial
sections demonstrated presence of the M1-like population in a pattern overlapping that for
CD11b, coinciding with regions of high macrophage activation within the granuloma’s
architecture (Figure 4B). The CD11b marker is present throughout the inflammatory foci,
with diffuse staining in most of the monocytic cells. There is also a number of CD11b+ cells
that are heavily stained; the presence of the CD38 marker appears to coincide with cells
also expressing the higher levels of CD11b. Of note, not all macrophages within the
granuloma exhibit CD38. Cells were also stained with anti-CD206 and anti-EGR-2, however
presence of these M2-markers were not detected (data not shown). Taken together with
the flow analysis, this suggests that the macrophages recruited to the focal inflammation
during the pulmonary granulomatous response induced by the TDM are of the M1-like
phenotype.
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Figure 4. Localization of CD11b+ and CD38+ Cells to Pulmonary Regions of Focal TDMInduced Inflammation. Serial sections of formalin fixed lung tissue were reacted with
antibody to CD11b (A) or CD38 (B), and subsequently visualized by way of standard HRP
staining techniques. The acute regions of inflammation demonstrate the overlapping
presence of both populations of cells within focal granulomatous regions. Representative
section, 100x magnification.
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Discussion

The establishment of the Mtb induced granuloma is a complex interaction of
multiple cell phenotypes responding to a myriad of antigenic stimuli [172]. A multitude of
studies have focused on mechanisms underlying development of the induced inflammatory
response leading to development of this pathology. Clearly, the influence of any one
specific molecule may not form an essential pathological bias in vivo during infection.
However, a deficiency in production of purified cord factor, trehalose 6,6’-dimycolate [173],
or manipulation of its structure [174], has certainly been shown to affect development and
morphology of the early granulomatous pathology.

TDM has been identified as an immune mediator of both innate and adaptive
inflammatory responses, and has been detailed as a virulence factor in reports focused on
animal models [175]. Others have examined its link and relevance to human disease by
descriptive comparisons to human pathological manifestations [21]. The nature of the
induced pathology is clearly defined by physical parameters [176, 177]. Experiments using
deficient mice allowed delineation of events that lead to establishment of the TDM-induced
inflammatory granulomatous response [159]. Furthermore, investigators identified innate
receptors that trigger distinct immune events [178]. This is the first report to our knowledge
that examines the influence of TDM on accumulated M1-like or M2-like phenotype
macrophages to the induced pulmonary foci. The results indicate that the presence of the

34

M1-like surface marker expression was significantly upregulated in TDM treated animals, as
opposed to the WT control animals, following the TDM induced granulomatous response.

Our in vivo studies show a significant increase of CD86 expression on CD11b+CD45+
cells within pulmonary foci. This population may have been recruited from alveolar spaces,
as shown to occur by Cohen, et. al, during Mtb infection [179]. At this time, it is unclear if
the identified macrophages arrive as a committed M1-like population, or if the environment
induces relative M1/M2-like pathology progression once cells arrive to the focus of
inflammation. Other groups have identified cellular plasticity in immune cell phenotypes
post arrival to pulmonary tissue post infection [180]. This may explain conflicting data from
Kan-Sutton, et al., where they found that TDM produced nearly identical strong proinflammatory effects in purified BMMs without inducing changes in surface expression of
CD86 [46]. Although difficult to compare in vivo and in vitro effect, it may be that the
discrepancy between these studies was due to the nature of the presented TDM. KanSutton used TDM adhered to the surface of beads; this format of exposure to TDM likely
measured internalized effects on intracellular mechanisms associated with mycobacterial
mycolic acid function, rather than those triggered via extracellular receptors. Our laboratory
has also previously shown that TDM impacts intracellular trafficking events [181, 182].
Indeed, the nature of the engagement of macrophage can influence phenotypic and
functional outcome [183].
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A brief discussion on the evidence for specific cellular receptors for TDM
engagement is warranted. Our data, along with previous findings on host macrophage
receptors MARCO [160] and Mincle [39, 184, 185], and Mincle-related Clec4d [186], suggest
a potential link between the existence of M1-like phenotype and engagement of those
putative TDM receptors. An intriguing finding by Bowdish et al., indicated that TDM
engagement with MARCO activates the TLR2 signaling pathway, with the end result of
production of similar pro-inflammatory cytokines to those identified in our study;
macrophages from mice lacking MARCO also produced a significantly reduced amount of
TNF-α, IL-6, and IL-1β in response to virulent Mtb. In our model of TDM “infection”, we
observed a similarly strong pro-inflammatory response in lung tissue. However,
engagement of the Mincle receptor could just as likely predict an M2-like outcome;
Schoenen, et al. elegantly linked Cebpβ and Hif1α nuclear signaling pathways to TDM
responsiveness in macrophages, with the end result of EGR (M2-like marker) synthesis
[187]. Likely, phenotypic outcome is regulated through multiple receptors. A related Mincle
ligand, the shorter chain TDM analog trehalose dibehenate (TDB), was also shown to
differentially modulate M1-like (and M2-like) macrophage phenotypes, through Syk
signaling processes [188]. Both Syk- and CARD9 pathway interactions have shown to then
further engage development of directed hypersensitive responses [189, 190], as well as
inflammatory signaling pathways [191]. Perhaps additional experiments comparing
trehalose 6-monomycolate (TMM) or galactose-galactose 6,6' dimycolate (GDM) may shed
light on the inflammatory response leading to presence of the M1-like phenotype found in
this study. However, these molecules have previously shown limits, as they do not induce
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MTB-like primary granulomas in oil-in-water emulsions. Nor do they engage macrophages in
the same manner as TDM [181, 192]. Therefore, although we might expect little change in
M1 markers on recruited cells due to TMM or GDM because of the lack of inflammation,
those molecules may provide a handle on pathways related to development of the M1-like
phenotype following TDM administration.

The rationale for induction of a strong macrophage pro-inflammatory response has
been suggested to promote signals resulting in induction of differentiated hypersensitive
populations [193]. Mtb has been shown to regulate internal pathways that may dictate
polarity of macrophages [194]. Multiple antigens from tuberculosis spp, in addition to the
mycolic acids, have been shown to trigger strong pro-inflammatory responses, which, again,
are likely dependent upon receptor engagement. For example, specific engagement of CD38
affects polarization of Th1 immune responses to M. avium [195]. Other molecules, such as
ESAT-6, demonstrated a mixed reported transitional function. Refai, et al., demonstrated
that ESAT-6 drives macrophages to the M1-like phenotype, although in the presence of TLR2 engagement it may exert anti-inflammatory M2-like polarization activity [196]. Huang, et
al. reported that ESAT-6 contributes to primary innate granuloma formation by inducing an
M1-type differentiation, occurring in the presence of strong IFN- activity. However, they
also indicated that this was likely dependent on the stage of infection in which this molecule
was examined (as well as presence of external mediators); ESAT-6 was shown to drive
macrophages toward an M2-like phenotype at the later stages of the infection. Regarding
Mtb antigens “in total”, they have been shown to induce a robust M2-like phenotype of
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human macrophages over time [197], with a shift away from CD86 towards CD206 surface
expression in in vitro models. Those findings were consistent with presence of M2-like
antigens seen on cells in various stages of post-primary granulomas from infected patients.
However, it should be noted that these represent stages of infection occurring well after
granuloma formation and Th1 infiltration, which is not seen in our results. Indeed, in our
hands, we did not see reactivity to M2-like markers CD206 or EGR-2 in our histological
sections. Therefore, the findings discussed do not preclude the results here.

Overall, the results presented support the hypothesis that purified TDM by itself can
be a strong inducer of a M1-like polarization of macrophages. As such, it continues to be an
effective tool to experimentally define the cross-regulation of inflammatory molecules and
cellular recruitment cascades which culminate in pathological changes in models of lung
granulomatous disease caused by Mycobacterium tuberculosis infection.
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CHAPTER 3: LACTOFERRIN REDUCES MYCOBACTERIAL TREHALOSE 6,6’-DIMYCOLATE
INDUCED M1-TYPE INFLAMMATION AND PERMITS FLUOROQUINOLONE ENTRY TO
GRANULOMAS

This chapter is reprinted from The Biochemistry and Cell Biology Journal, Volume 99, Issue 1,
Thao K T Nguyen , Zainab Niaz , John d'Aigle, Shen-An Hwang, Marian L Kruzel, Jeffrey K
Actor, “Lactoferrin reduces mycobacterial M1-type inflammation induced with trehalose
6,6'-dimycolate and facilitates the entry of fluoroquinolone into granulomas”, Page 73-80,
Copyright (2020), with permission from Elsevier. (https://doi.org/10.1139/bcb-2020-0057)

Introduction

The Mycobacterium tuberculosis (Mtb) cell wall cording factor, trehalose 6,6’dimycolate (TDM), is a physiologically-relevant and useful molecule for modeling early
macrophage mediated events during establishment of the tuberculosis-induced granuloma
pathogenesis. Recent findings support the hypothesis that this mycobacterial mycolic acid
can specifically recruit M1-like polarized macrophages [198], occurring in the absence of a
significant M2-like phenotypic response. Many observers hypothesize that the initial strong
M1-like biology contributes to creation of a microenvironment essential to limit
dissemination of the bacilli [146]. On one hand, this leads to containment of the Mtb in
infected macrophages within circumscribed granulomas [43]; this is advantageous to the
host. However, this containment has the negative effect of also protecting sequestered
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organisms from immune-mediated killing by immune effector cells which are unable to
effectively penetrate the granulomatous structure [70].
No current therapeutic modalities focus to modulate host immune responses to
ameliorate tuberculosis disease [199, 200]. The molecule lactoferrin (LF), a natural ironbinding protein found within neutrophils, is a proven modulator of inflammation [93, 201]
which is active in immune functions [202] as well as in host defense [203, 204]. In our
hands, bovine-derived LF was able to ameliorate TDM-induced granuloma cohesiveness
[205]. This could be clinically advantageous, with potential function for LF to permit
recruited cells entry into a densely populated pathological area. Relating this to models of
mycobacterial infection, LF was shown to modulate the pulmonary granulomatous response
induced during Mtb challenge, with no loss of adaptive response or increased dissemination
of organisms to tissues peripheral to lungs [206].
Furthermore, organisms within granulomas are isolated from efficiently delivered
anti-mycobacterial due to the compact nature of the pathological structure [31, 43, 207].
Thus, an increase in current therapeutic efficacy may be achieved through incorporation of
adjunct components that curtail development of aggressive destructive pulmonary
pathology. LF was able to mediate a change in cohesiveness of the granulomatous response
during model systems of granulomatous response. Therefore, LF may ultimately function as
an adjunct therapeutic, serving as a novel strategy for TB disease treatment.
We therefore investigated a recombinant human version of lactoferrin (rhLF)
expressed in a CHO cells [208] to modulate the TDM-induced granulomatous pathology.
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Experiments were designed to address if LF would serve as an adjunct molecule for
increased penetration of anti-mycobacterial agents to regions of granulomatous pathology
induced in mice. Furthermore, as an initial investigation into a possible mechanism of
action, specific markers of M1- and M2-like macrophages [65] were evaluated to determine
if rHLF alters the phenotypic profile of recruited macrophages post induction of the TDM
response.

Materials and Methods

Mice. Female C57BL/6 mice (Envigo, Houston, TX) of five to six weeks of age, and
approximately 20g weight, were incorporated into the studies. All in vivo work was
completed at the University of Texas Health Science Center (UTHSC), according to approved
protocols (animal welfare ethics committee document HSC-AWC-17-0089). The work was
completed under animal welfare ethical guidelines established at the UTHSC, with
conditions detailed in the approved animal welfare document.
TDM-Induced Pathology. Mycobacterial-derived trehalose 6,5’-dimycolate (TDM;
cord factor) (Enzo Life Sciences, Farmingdale, NY) was given as an oil/water emulsion
prepared as described [159, 198], intravenous (IV), at a volume of 100 μl per animal. Control
mice received material formulated with no addition of TDM; controls did not exhibit
inflammation, as previously reported [158, 163]. All mice were sacrificed at times indicated
post injection of formulated material.
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Lactoferrin and Ofloxacin. Recombinant human lactoferrin (rHLF; LFH-101; endotoxin
<10 EU·mg−1) was kindly provided as lyophilized powder by PharmaReview Corporation
(Houston, TX.). Mice were given 1 mg rHLF in a 100 μL volume by oral gavage [209, 210] at
day 3 and 6 after TDM injection. The two dose administration schedule was chosen to
match the initiation phase and establishment of granuloma development in this model, and
levels previously seen effective using bovine derived lactoferrin [209].100 μL volume of 30
mg/ml ofloxacin (Sigma Life Science; O8757-1G), solubilized in DMSO and diluted 1:10 with
PBS, was intraperitoneal administered 30 minutes prior to sacrifice.
Pulmonary Cytokines. Lungs were excised, homogenized, and incubated at 37oC and
5% CO2 for at least 2 hours in Dulbecco’s Modified Eagle’s medium (DMEM) that contained
50 μg/ml L-Arginine, 100 μg/ml penicillin, 50 μg/ml gentamycin, 50 μg/ml HEPES, and 10%
fetal bovine serum. Collected supernatants were examined by enzyme-linked immunoassay
(ELISA), as previously detailed [198], for the presence of TNF-α, IL-1β, IL-10 and TGF-β
following manufacturer’s instructions (DuoSet kits, R&D Systems, Minneapolis, MN). TGF-β
samples were pretreated with 1:5 ratio of 1N HCl, then neutralized. Results were calculated
by a standard curve produced to manufacturer’s recombinant molecules.
Histological Assessment. The mouse lung large right lobe was perfused with 1mM EDTA in
phosphate buffered saline, fixed in 10% buffered formalin (Fisher Scientific, Pittsburg, PA),
embedded in parafin, sectioned (5 μm thick), and stained with with hematoxylin (Surgipath,
Richmond, IL) and eosin (Richard-Allen Scientific, Kalamazoo, MI) as per standard
procedures at the Histology Laboratory at the UTHSC McGovern Medical School (Houston,
TX). H&E stained slides were then used to capture photos of granulomas under the Olympus

42

BX51 microscope using the Nuance Cri Multispectral Imaging System FX (PerkinElmer). The
granuloma section was first identified and captured under H&E brightfield staining, then
Ofloxacin’s fluorenscent signals were captured under 40x lens with FITC filter (emmission
restriction set between 540nm to 560nm) after 120ms of exposure. All microscopic settings
and factors were maintained throughout the photo taking process. All image files have the
same dimensions of 1392 x 1040 with 72 dpi resolution.
Computerized Analysis. High resolution scanned images of H&E stained slides were
assessed for lung inflammation using Motic DSAssistant software (Kowloon Bay, Kowloon,
HK), in a two step process using Fiji ImageJ (Version 1.52o 23 April 2019, National Institutes
of Health, Bethesda, MD) with plugin MorphoLibJ [211], described in part in [198].
Minimum and maximum values for hue, saturation, and brightness were set at: 120, 255; 0,
255; and 0, 255, respectively. Total cell area measurement used a modified version detailed
elsewhere [212] where peak threshold was set at 164, similar to published examples [166].
Values were averaged within treatment groups and normalized to non-treated controls. For
each granuloma, the total fluorescent area (ofloxacin absorption) and the total granuloma
area were measured in pixel units using CellProfiler (software version 3.1.5) pipeline
algorithm [211], with described modifications [213]. Background was eliminated by the
measured average fluorescence signal from control mouse lung H&E-stained histological
slides using CellProfiler.
Flow Cytometry Analysis. Flow cytometric assessment was performed as previously
done by Nguyen, et al. [198]. Briefly, lungs were extracted from WT, TDM and TDM/LF
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treated mice. Homogenized tissue was treated for 30 minutes with
Collagenase/Hyaluronidase (StemCell Technologies) and DNAse I (Sigma) in RPMI-1640 with
1% 100X pen/strep and 2.5% HEPES (Thermo Fisher Scientific), and 5% HI FBS (Corning).
Cells were purified prior to staining using a 70% GE Healthcare Percoll (Cat# 17-0891-01)
gradient Surface markers chosen to delineate murine M1-like and M2-like macrophages
were based on published data from Jablonski, et al., [65], later detailed by Orecchioni, et al.
[168]. Similar findings were identified in human monocyte-derived macrophages [169]. Cells
were stained in accordance with manufacture recommendation, using Live Dead Aqua
(eBioscience, L34966) for 15 minutes, then FC (antibody receptor) blocked with Anti-Mo
CD16/CD32 (eBioscience, 14-0161-86) for 15 minutes. Staining used the following
antibodies against specific receptors: CD38 (Biolegend, Cat# 102728) APC/Cy7, CD86
(Biolegend, Cat# 105014) PE/Cy7, CD206 (Biolegend, Cat # 141704) FITC, EGR2 (eBioscience,
17-6691-82) APC, CD11b (Biolegend, Cat# 101208) PE, and CD45 (eBioscience, 48-0451-82)
eFluor 450 for 20 minutes. Cells were fixed with 2% paraformaldehyde, and evaluated on a
Beckmen Coulter Cytoflex S flow cytometer (Model No. B75442). Data was then analyzed
using FlowJo V10 (Becton Dickinson).

Statistical Analysis. Data presented are a combination of 2-4 experimental repeats.
Each experiment incorporated 3-6 mice per group. Data was reported as percent area and
compared between groups using a two-tailed t-test in GraphPad Prism, version 5.03.
Differences between means were considered statistically significant at a value of p≤0.05, or
otherwise indicated.
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Results

Lactoferrin Reduces TDM-Induced Lung Pathology.
Intravenous administration of the mycobacterial mycolic acid TDM, results in
development of defined inflammation in C57Bl/6 mice, which mimic many aspects of the
granulomatous reactions seen during infectious challenge with virulent Mycobacterium
tuberculosis. Using the well-defined TDM-induced granuloma model, the histologic
accumulation of monocytic cells within the lung readily occurs post TDM administration
(Figure 5). The number of focal accumulates grow in number, size and complexity through
day 7, resulting in occlusion of vascular regions and limitation of open alveolar
compartments (Table 1). Results are due to treatment with TDM; emulsion vehicle alone
was not able to induce morphological change [209]. Oral treatment with 1 mg of
recombinant human lactoferrin (rHLF) on days 2 and 4 post TDM administration markedly
reduced, but did not completely eliminate, the TDM-induced focal responses. Granulomas
were diminished by day 4, with significant reduction in both size and number (p<0.05) of
inflammatory accumulates at both days 4 and 7 post induction of the response.
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Figure 5. Lactoferrin Induced Reduction of Gross Pulmonary Granulomatous Inflammation
caused by TDM. Lungs from mice given TDM (B, E) were assessed after 7 days and
compared to control (A, D) or rHLF treated (C, F) animals. Histologic examination revealed
acute granulomas with monocytic cell infiltration and presence of focal, “foamy”
vesiculated macrophages, and occluded vascular regions. rHLF treatment markedly reduced
inflammatory response, with limited pathological damage to lung tissue. Formalin fixed lung
sections were hematoxylin and eosin stained; histopathology shown at 10x or 300x
magnification. Histographs represent sections obtained from repeated studies with 4 to 6
mice in each group.
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Granulomas/mm2

Granuloma Size (m2)

Day 4

Day 7

Day 4

Day 7

Avg (%)

3.88

7.79

16.73

40.52

STDev

1.15

1.38

2.23

4.97

Avg (%)

2.6

2.04*

12.47

17.74*

STDev

0.47

0.33

2.66

4.39

TDM

TDM + LF

Table 1. Lactoferrin reduction in TDM-induced inflammatory response. Histological
assessment of granulomatous inflammation was assessed at 4 and 7 days post
administration of TDM, with or without rHLF treatment. Average number and size of
inflammatory foci were measured, with standard deviation shown. N = 4 to 6 mice per
group; experiments were repeated at least twice. *p≤0.05.
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Decreased Pro-inflammatory Response in Lungs after Treatment with Lactoferrin.
Administration of TDM results in a strong pro-inflammatory response [214, 215]. The
cytokines TNF-α and IL-1β were assessed in lungs by ELISA to examine if the histological
changes due to the rHLF administration would also affect responses. Lungs were examined
following TDM administration, with or without rHLF treatment. There was significant
production of pro-inflammatory mediators TNF-α and IL-1β, which was significantly reduced
by the rHLF. (Figure 6). The anti-inflammatory cytokines were also examined; there was no
change, relative to TDM, in IL-10 production after additional treatment with the rHLF
(Figure 6). Similarly, there was no production of TGF-β, which was also not altered by
addition of rHLF (not shown).
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Figure 6. Lactoferrin reduced pro-inflammatory cytokines during TDM-induced pathology.
Assessment of inflammatory cytokines post treatment with rHLF revealed decreases in
production of TNF-α (left panel, A) and IL-1β (middle panel, B) within lungs at day 7 post
administration of TDM, compared to TDM alone treated mice. Mice receiving TDM did not
reveal significant changes in production of IL-10 (right panel, C); no alteration of this was
apparent in the rHLF treated group. Results represent mean ± standard deviation, data was
collected from 2 independent experiments with 4-6 mice in each group per experiment.
One Way ANOVA, p≤0.01, Tukey Post Hoc test for multiple comparisons: **p≤0.01 for IL-1β
TDM+rHLF vs TDM and ***p≤0.001 for TNF-α TDM+rHLF vs TDM.

49

Lactoferrin Treatment Increases Ofloxacin Penetration to Inflammatory Foci.
The histological complexity of the TDM-induced pathology has been previously
reported [214, 215]. Treatment with rHLF markedly altered the inflammatory response,
resulting in monocytic foci that were less dense. It was hypothesized that the physical
nature of the granulomas were altered in a manner to allow greater permeability of small
molecules, such as those useful in treatment of mycobacterial infection. To test this
hypothesis, mice were intraperitoneal administered the fluoroquinolone ofloxacin on day 7,
just prior to sacrifice. Visualization of lung histological sections prepared from the nontreated mice demonstrated presence of the naturally fluorescent ofloxacin therapeutic
agent evenly distributed throughout pulmonary vascular regions (not shown). In contrast,
the TDM alone treated mice demonstrated a relative exclusion of fluorescence penetration
into regions of inflammatory response (Figure 7, top left panel). This was expected, as the
compact nature of the granulomatous response results in small blood vessel occlusion
[215]; indeed, pockets of fluorescence can be readily visualized in occluded vessels. Of
interest, treatment with the rHLF was able to restore ability of the ofloxacin to penetrate
evenly throughout regions of granulomatous inflammation (Figure 7, top right panel). The
relative fluorescence was quantitated via software analysis; the rHLF treatment significantly
(p<0.001) increased the ability of ofloxacin to penetrate regions of focal inflammation
(Figure 7, bottom panel).
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Figure 7. Increased penetration of ofloxacin to granulomas post lactoferrin treatment.
Lungs from mice given TDM alone (top, left), or TDM plus rHLF treatment (top, right), were
assessed for presence of the fluoroquinolone ofloxacin. Ofloxacin penetration was limited in
the TDM alone group, except for regions of high vascular occlusion (red star). The rHLF
treated mice permitted entry of ofloxacin via penetrating vasculature (red arrows), and
entry within monocytic cells within the pathological foci. Histographs are shown at 40x
magnification. Quantitative assessment of relative fluorescence for individual inflammatory
foci are represented (bottom), with average and standard deviation included. One Way
ANOVA, p≤0.05, Tukey Post Hoc test for multiple comparisons: ***p≤0.001 for TDM+LF vs
TDM.
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Lactoferrin Reduces Accumulation of Recruited M1-like Macrophages.
It was recently shown that the TDM-induced granulomatous inflammation was
comprised of recruited monocytic macrophages primarily of the M1-like phenotype [198].
Cells were isolated from TDM-induced lungs at 7 days post treatment, and CD11bhiCD45hi
macrophages [170, 171] were examined by flow cytometry for presence of M1-like and M2like surface markers. Table 2 depicts data collected for M1-like markers CD38 and CD86,
and for the M2-like markers CD206 and the early growth response gene-2 (EGR-2).
Treatment with TDM resulted in an overall accumulation of CD11bhiCD45hi cells that was
approximately 1.77-fold (+/- 0.19-fold) compared to the rHLF treated group. The TDM alone
cells expressed higher M1-like markers, but not the M2-like surface proteins. The M1-like
marker CD38 was present on 24.70% +/- 11.18% of recruited macrophages. CD86 was
present on 12.34% +/- 3.37.48% macrophages. Overall, there were fewer recruited
macrophages to the lungs in the rHLF treated mice. In addition, the M1-like markers on
these cells were markedly reduced in the rHLF treated group. Specifically, there was a
significant reduction in both CD38 (10.19% +/- 1.16%; p<0.05) and CD86 (3.98% +/- 0.73%;
p<0.001). There was a modest (non-significant increase) in M2-like makers in the rHLF
treated group compared to TDM alone, however, this was comparable to the non-treated
control animals.
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M1-Like Markers
CD38

M2-Like Markers
CD86

CD206

EGR2

Control

N=3

Avg (%)

7.76

5.31

1.24

0.11

STDev

2.24

0.61

0.16

0.05

TDM

N=6

Avg (%)

24.72

12.34

0.53

0.15

STDev

11.18

3.37

0.35

0.07

TDM + LF

N=4

Avg (%)

10.19*

3.98**

1.13

0.11

STDev

1.16

0.73

0.71

0.04

Table 2. Assessment of M1/M2-like Markers on Infiltrating Monocyte-Macrophages.
Isolated CD11bhiCD45hi macrophages from lungs at 7 days after administration of TDM were
examined for the M1-like markers CD38 and CD86, and for the M2-like markers CD206 and
EGR-2. Comparisons are made to rHLF treated mice. Average percent values with standard
deviations are given for each marker; control values shown were previously reported [198].
One Way ANOVA, p≤0.05, Tukey Post Hoc test for multiple comparisons: *p≤0.05 for C38
TDM+LF vs CD38 TDM and **p≤0.001 for CD86 TDM+LF vs TDM.
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Discussion

The results presented in this study confirm the utility of LF to ameliorate primary
granulomatous inflammation [205, 206] and permit entry of therapeutic molecules to sites
of macrophage mediated pathology. LF has been extensively examined as a mediator of
inflammatory responses (reviewed in [201, 216]), interacting directly with pathogens [217]
and controlling host immune homeostasis [218, 219]. Indeed, recombinant human LF is
adept at regulating induced macrophage inflammatory responses [220], functioning well as
an immune-therapeutic in models of animal sepsis and SIRS [221] and oxidative stress [222].
The experiments outlined here extend our previous findings to show that rHLF can alter
MTB-like primary pathology, and specifically modulate TDM-induced inflammation [210] to
further allow penetration of therapeutic molecules to sites of immune reactivity.
The TDM-induced granulomatous response is a well-accepted model, if not a
simplified model, of the primary pathology seen during mycobacterial infection [21].
Primary tuberculosis infection is defined as a mixed macrophage and adaptive cellular
response. Marino, et al., hypothesized that macrophage phenotypes drive the
granulomatous response during MTB infection [147], where the initial response is mediated
by an M1-like macrophage phenotypic recruitment with balanced contribution from M2-like
responders as disease progresses [146]. This fits into known processes for granuloma
regulation, where an initial M1-like proinflammatory response characterized by production
of TNF- is required for development of pathology [223, 224]. Marakala, et al., further
hypothesized that polarized M1 macrophages are recruited, altering the natural M2-like
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anti-inflammatory environment of the alveolar macrophages which first encounter inhaled
organisms. This series of events thereby initiates a protective environment to encapsulate
bugs into a defined spatial region [142].
The first antigens encountered during mycobacterial infection are likely to be
surface mycolic acids [21]. Khan, et al., suggested that these molecules alter the plasticity of
macrophages during initiation of the granulomatous response [60]. Although it remains to
be determined if macrophages undergo true polarization events during first encounter with
mycobacterial antigens, Nguyen, et al., reported that the phenotype of recruited
macrophages during the TDM-induced response is of the M1-like phenotype [198]. This
phenomenon was reconfirmed in the results presented here. Our results show that the
addition of LF during inflammation induced by the TDM mycolic acid led to a decrease in
presence of M1-like macrophages. An object of further study would include LF’s direct
effect on macrophage polarization. Of interest, Gao, et al. used an immunocomplex
containing LF to polarize towards M1-like activity [225]. However, that observation was
likely due to the construct used, which contained a linked immunoglobulin Fc region that
likely interacted with macrophage receptors to alter cellular responsiveness. The results in
this report use a purified LF that was not complexed to other molecules.
Host-directed therapies to combat tuberculosis pathology are a promising approach
for new treatment modalities [226, 227]. The concept to regulate TNF- as a method to
control mycobacterial infection has been explored in the literature [228]. This is a doubleedged sword; too much TNF- results in tightly packed mycobacterial granulomas, while its
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complete absence is detrimental to initiation and development of a protective pathology
[214, 224]. LF, as an adjunct host-directed therapeutic, has demonstrated effects on
macrophages to limit, but not eliminate, TNF- [220, 221]. In the studies presented here, LF
was useful to decrease the magnitude of the M1-like phenotype, in essence functioning as a
host-directed adjunct therapeutic in a non-infectious model of tuberculosis primary
infection.
Interest is high in LF as a therapeutic agent to control inflammation and prevent
sepsis in neonates, with several clinical trials completed or still in progress [229-233].
Mechanistically, administration of LF may exert anti-inflammatory effects in newborns
through modulation of myeloid suppressor cells which are present in high numbers early in
life [234]. In vitro, LF was able to convert newborn monocytes to MDSCs, with subsequent
activity to control inflammatory pathology [235]. The utility of LF to convert cell phenotypes
may be similar to alteration of the monocyte phenotypes noticed in this report, however,
the concept requires further investigation. At this time, it is not known if the change in
recruited macrophage phenotypes is directly due to changes in polarization or in selective
recruitment in our model system.
The fact that LF was successful as an oral administered agent is a bonus to future
clinical use. At this time, it is unclear how LF functions systemically, since it is known to
undergo proteolytic degradation in the gastrointestinal tract by digestive enzymes [236,
237]. It was recently reported that inflammatory pathways identified in transcriptome
profiles of oral delivered rHLF significantly overlapped with those of intravenous
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administration (M.L. Kruzel, unpublished communication, [238]). While this study was done
in rats, it appears that LF-induced effects are systemically transduced, even if the protein is
degraded in transit.
Formation of a densely packed granuloma essentially limits efficacy of immune
effector cells. Modulation of the magnitude of the granulomatous response could
potentially overcome the ability of the organism to escape immune-mediated killing,
limiting the compact physical nature of the sequestration of infected cells and allowing
effector cell access to the infected nidus. Indeed, oral delivered bovine LF was shown to
control pulmonary granulomas in models of MTB infection, without loss of adaptive
response or subsequent increase in organism dissemination to other tissues [206, 210].
There are numerous advantages for limited disruption of the primary granuloma during
mycobacterial infection, especially if organisms remain contained. Of major interest relative
to the findings presented here would be increased drug penetration to sites of compact
pathology which harbor infectious agents. The advantages of increased drug penetration to
areas where organisms reside include a greater ability to overcome drug resistance
development in slowly replicating pathogens, and limitation of toxicity complications with
potentially shorter duration of therapeutic treatment times. Ofloxacin, a naturally
fluorescent anti-mycobacterial analog of the effective fluoroquinolone therapeutic
ciprofloxacin [239, 240], was used in these studies because it permitted detection using a
multispectral fluorescent imaging system without addition of modifying tags for detection.
LF treatment correlated highly and significantly with the ability of ofloxacin to penetrate
into granulomas. It was our subjective impression that while the penetration of ofloxacin
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occurred more readily in smaller granulomas, there was increased fluorescence in nearly all
inflammatory foci in the LF treated groups, irrespective of granuloma size.
Overall, the recombinant human LF served as an adjunct molecule for increased
penetration of anti-mycobacterial agents to regions of induced granulomatous pathology.
Mechanistically, this correlated with a shift away from the presence of M1-phenotypic
macrophages at the site of pathology. Future studies will investigate the role of LF to alter
polarization of inflammatory macrophage phenotypes responding to pathogenic signals.
Furthermore, it will be critical to examine LF as an adjunct therapeutic to enhance
penetration of antimycobacterial agents during tuberculosis disease, as a way to augment
therapeutic treatment to control infectious-related pathology. In addition, the mechanisms
of oral delivered lactoferrin must be further investigated.
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CHAPTER 4: RECOMBINANT HUMAN LACTOFERRIN REDUCES INFLAMMATION AND
INCREASES FLUOROQUINOLONE PENETRATION TO GRANULOMAS DURING
MYCOBACTERIAL INFECTION

Introduction

Despite world-wide extensive research and eradicating efforts, Mycobacterium
tuberculosis (Mtb) remains a major infectious pathogen to the human population with
approximately 10.0 million infected cases and 1.5 million deaths reported in 2020 globally
[241]. The initial host-pathogen interaction, and complex immunological responses,
culminate in an inflammatory pathology within pulmonary tissue which is characterized as a
primary granulomatous disease [21, 242]. These granulomas and associated lesions obstruct
normal pulmonary functions. Active research investigates how Mtb directly induces the
granulomatous response, focusing on areas of pathological damage and bacterial burden
that are most severe during primary infection.

Mtb associated factors are involved in the recognition and activation of host cells
within the bronchial regions, leading to uptake by alveolar macrophages [34]. This
interaction triggers a series of immune responses via the production and release of
cytokines by infected and responding macrophages [243]. For example, trehalose 6'6dimycolate (TDM), an abundant mycobacterial mycolic acid, directly triggers a
granulomatous response [21, 198]. TDM-activated macrophages release pro-inflammatory
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mediators, such as TNF- and IL-1-β, along with additional chemotactic factors, to further
recruit immune cells to areas of infection [36, 40, 244]. Over time, additional recruited
immune cells participate in formation of organized, sphere-shaped primary inflammatory
structures at the infected site [42]. There exists a balance between host and organism; the
granulomas formed during active Mtb infection contain and limit bacterial dissemination
[43], yet organisms have adopted mechanisms to survive and grow inside macrophage host
cells. Indeed, recruited naive macrophages can become new potential sites for Mtb to
shelter and replicate [47].

Clinically, the physical nature of the granuloma also limits penetration of antimycobacterial therapeutics; as granulomas mature, reduction in vascularization limits drug
delivery to within granulomas where large populations of Mtb may reside [48, 49, 70]. The
physical nature of the host immune response therefore represents a challenge in treating
Mtb-infected patients – it contributes to prolongation of treatment while permitting a small
population of Mtb to escape elimination. The lack of complete penetration of
antimycobacterial agents also indirectly increases risk of developing antibiotic-resistance
[245-247]. Therefore, multiple lines of investigation currently are aimed at improving drug
delivery through focused targeting to either the manipulate the granuloma structure, or to
augment immune responses to Mtb that lead to granuloma development [248].

Novel approaches to Mtb treatment include host-directed therapies [76] which are
focused in two major fronts; the first augments immune response using immune-based
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treatments [77], while the second alters the resultant immunopathology [78]. Examples of
immune-based treatment methods include agents that target the macro-autophagic
compartment, such as vitamin D and retinoic acid, which increase phagocytosis to augment
the lysosomal degradative processes inside macrophages [79]. Ibuprofen, an antiinflammatory drug, functions as an adjunct treatment by facilitating pyrazinamide to
alleviate pathological damage in the lungs [77, 80, 81]. These immune-based approaches
have significant potential, demonstrating superior disease outcomes in clinical trial results
[249, 250]. While promising, the obstacle in drug delivery to macrophages inside
established granulomas persists [84]. Therefore, therapies that target pathologies, in
addition to antimycobacterial function, may subsequently be more useful as clinical tools. A
well-known example of the immunopathological alteration approach is blocking excess TNFα, a key pro-inflammatory cytokine required for granuloma formation [224, 251]. TNF-α
inhibitors have been used to treat other inflammatory diseases effectively [85-87].
However, its current downside is that TNF-α inhibitors can lead to increased bacterial
dissemination; abolishing the granuloma containment modality runs the risk of Mtb
reactivation [88-91].

Lactoferrin, a glycoprotein known for its ability to bind iron, has been extensively
studied for its role as an immune modulator in host defense in disease models [219, 252]. It
falls into the category of “immune modulators”, and has been identified to reduce
pathology of the tuberculoid granuloma [92]. In addition, lactoferrin has been shown to
boost immune memory response in vaccine models, while reducing pro-inflammatory
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response in lipopolysaccharide (LPS) exposed mouse models [93, 94, 96, 97, 253]. Relative
to the study described in this report, bovine lactoferrin significantlly reduced inflammatory
pathology in TB-infected mice [98]. Both human and bovine lactoferrins were also shown
effective to limit inflammation in the non-infectious TDM-induce granuloma mouse model
[78, 99].

Lactoferrin treatment reduced the M1 phenotypic response to TDM, and limited
pathological damage in murine lungs [78, 198]. The lactoferrin treatment also significantly
increased penetration of the second-line anti-mycobacterial agent Fluoroquinolone into
TDM-induced granulomas [78]. Such anti-inflammatory response in the lactoferrin-treated
mice, along with other data showing lactoferrin reduces pro-inflammatory phenotypes in
macrophages [136, 137], suggests that lactoferrin had a modulating pro-inflammatory
response on granulomas. The studies presented here extend theses observations to
examine if lactoferrin can modulate granuloma permeability and drug distribution during
active Mtb infection. Here, the effect of lactoferrin on the permeability of granulomas to
fluoroquinolones is examined in the Mtb-infected mouse model, when administered as a
prophylactic (prior to granuloma formation) or therapeutic (after granuloma establishment)
intervention. These experiments shed light on mechanisms underlying changes to the Mtb
pathological events due to lactoferrin adjunct treatment.
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Materials and Methods

Mice. Five-week-old female C57BL/6 mice were purchased from Envigo (Houston,
TX) with 18-20 grams initial body mass. Eight to ten mice were used per group, per time
each point indicated. All Mtb infections occurred in biosafety level 3 facilities under the
University of Texas Health Science Center at Houston institutional guidelines (IBC-18-014),
with approval from the animal ethics committee (AWC-17-0089).

Recombinant human lactoferrin and ofloxacin, and delivery to mice. CHO-expressed
recombinant human lactoferrin (rHLF; >98% purity; <10% iron saturated; <0.5 EU·mg−1; Cat#
LFH-101) was kindly provided as lyophilized powder by PharmaReview Corporation
(Houston, TX) [254, 255]. The rHLF was reconstituted in dH2O to a concentration of 1 0
mg·mL-1. From day 14 to day 28 after Mtb infection, mice were given 1 mg·(100
μL)−1·mouse−1 of rHLF by oral gavage every other day as prophylatic treatment, similar to
reported use in models of mycobacterial granulomatous responses [92, 209, 210]. 1 mg/ml
was found to be more productive than a 100 μg/ml dose (Figure 8). From day 21 to day 28
after Mtb infection, another group of mice were given 1 mg·(100 μL)−1·mouse−1 of
recombinant human lactoferrin by oral gavage every other day as therapeutic treatment.
Ofloxacin (Sigma Life Science; O8757-1G) was given at 100 μL of 30 mg·mL-1·mouse-1,
solubilized in DMSO and diluted 1:10 with PBS, was intraperitoneal administered 30
minutes prior to sacrifice [256].
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Figure 8. Lactoferrin treatment reduces pulmonary inflammation post infectious challenge
with Mtb in a dose dependent response. Lungs from Mtb infected mice were assessed at
day 28 post aerosol infection (A) and compared to animals given bovine LF in the
prophylactic group (B,C) or therapeutic group (D,E). Histologic assessment revealed primary
granulomatous response with monocytic cell infiltration, dense cellular foci, and occluded
vascular regions in control infected mice. Both prophylactic and therapeutic rHLF treatment
reduced inflammatory response resulting in modest inflammatory foci and reduced
pathological damage to lung tissue. While both doses (100 g and 1 mg levels) were
productive in limiting focal inflammation, the higher dose was more consistent between
treatment groups. Hematoxylin and eosin stained histographs represent formalin fixed lung
sections at 10x magnification obtained with 8 to 10 mice in each group; study
representative of repeat experiments.
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Mtb infection. Aerosol infections were done as previously reported [253, 257], using
Mycobacterium tuberculosis, strain Erdman (TMC 107, American Type Cell Culture).
Organisms were cultured in Middlebrook 7H9 broth with 10% supplement (5% bovine
serum albumin, 2% dextrose, and 0.5% Tween 20 in distilled water) to log phase. Pelleted
bacteria were resuspended in phosphate buffered saline (PBS) and diluted to 3 × 108 colony
forming units (CFU) per ml using McFarland standards. Bacteria were sonicated to disperse
aggregates. The bacterial CFUs for each time point, including day 1 post infection, were
confirmed by plating serial dilutions on Middlebrook 7H11 agar plates (Hardy Diagnostics,
Santa Maria, CA) using the large right lobe of the mouse lung that was weighed and
homogenized into 2 mL PBS, which were incubated at 37 °C for 3 – 4 weeks. Mice were
infected for 4 weeks, with treatments described above, using the protocol shown in Figure
9. Bovine lactoferrin, shown to have biological equivalency to the rHLF [92] was used for
analysis of CFU dissemination to other organs and to reconfirm bioequivalence in dose
response treatments (Figure 10).
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Figure 9. Mtb infection and lactoferrin treatment scheme. C57Bl/6 mice were aerosol
challenged with Mtb and treated with rHLF administered every other day orally beginning
on day 14 (prophylactic; 6 total doses), or beginning on day 21 post infection (therapeutic; 3
total doses). Mice were intravenous injected with ofloxacin 30 minutes prior to sacrifice, at
28 days post initial infectious challenge.
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Figure 10. Mycobacterial burden in lactoferrin treated mice. C57Bl/6 mice were aerosol
challenged with Mtb, strain Erdman, and treated with bovine lactoferrin (bLF) given as 100
µg or as 1 mg dose administered every other day orally beginning on day 14 (prophylactic
treatment), or beginning on day 21 (therapeutic treatment) post infection. Lung (A), spleen
(B) and liver (C) were removed on day 28 post infection; tissues were assessed for bacterial
CFUs confirmed by plating serial dilutions on Middlebrook 7H11 agar plates using the large
right lobe of the mouse lung that was weighed and homogenized into 2 mL PBS, which were
subsequently incubated at 37 °C for 3 to 4 weeks and represented as CFU burden per organ.
Data are presented as individual mice with the mean and SEM indicated, n  6 mice per
group. One Way ANOVA, p0.05, Tukey Post Hoc test for multiple comparisons.
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Histological assessment. The small left lobe of the mouse lung was collected and
fixed in 10% buffered formalin. For histologic analysis, the lung was sectioned (5 μm thick)
and stained with hematoxylin and eosin (H&E) and acid-fast staining as per standard
procedures [253]. The histological assessment of the lung tissue following aerosol infection
was done as previously reported [257]. Multiple sections from at least 6 mice per group
were analyzed using Motic DSAssistant digital software (version 1.0.7.44; Kowloon Bay,
Kowloon, HK) [78]. H&E stained and acid-fast stained slides were viewed by a trained
pathologist, with descriptive results obtained in an experimentally blinded manner.

Immunohistochemistry. Fixed lung was embedded in paraffin, sectioned, and stained
for immunohistochemical examination, similar to methods described [258], diluted at
1:2000, was performed according to manufacturer’s instructions with a modification of 20
minutes at low pH for antigen retrival, and visualized using standard HRP techniques and
DAB chromogen using Dako reagents (Dako, Agilent, Santa Clara, CA). In a similar manner,
M1-like marker CD38 (Invitrogen, ThermoFisher, Cat# 14-0381-02), diluted at 1:1000, M2like marker CD 206 (Bioss, Cat# bs-4727R), diluted at 1:1000, and endothelial cell marker
CD31/PECAM-1 (Cell Signaling, Cat# 77699T) diluted at 1:200 was used for visualization on
serial slide sections. Hematoxylin counterstained slides were viewed by a trained
pathologist, with descriptive results obtained in an experimentally blinded manner.

Quantitative assessment of pulmonary inflammation. High resolution scanned
images of H&E-stained slides were assessed for lung inflammation and granulomas using
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Motic DSAssistant software (Kowloon Bay, Kowloon, HK), in a two-step process using Fiji
ImageJ (version 1.52o 23 April 2019, National Institutes of Health, Bethesda, MD) with
plugin MorphoLibJ (McQuin et al. 2018), described in part in [78]. Minimum and maximum
values for hue, saturation, and brightness were set at: 120, 255; 0, 255; and 0, 255,
respectively. Total cell area measurement used a modified equation detailed elsewhere
where peak threshold was set at 164 [166]. Values were averaged within treatment groups
and normalized to non-treated controls. H&E-stained slides were also used to capture
photos of granulomas under the Olympus BX51 microscope using the Nuance Cri
Multispectral Imaging System FX (PerkinElmer). The granuloma section was first identified
and captured under H&E brightfield scope, then ofloxacin’s fluorescent signals were
captured under 40x lens with FITC filter (emission restriction set between 540nm to 560nm)
after 120ms of exposure. All microscopic settings and factors were maintained throughout
the photo taking process with image files having the same dimensions of 1392 x 1040 with
72 dpi resolution. For each granuloma, the total fluorescent area or ofloxacin absorption
area and the total granuloma area were measured in pixel units using CellProfiler (software
version 3.1.5) pipeline algorithm [211], with described modifications [213]. Background was
eliminated by the measured average fluorescence signal from control mouse lung H&Estained histological slides using CellProfiler. The measurement on the selected lung section
is reported as percent area that represents the ratio of ofloxacin absorption over the total
granuloma area. All data was graphed and statistical analyzed in GraphPad Prism (version
5.03).
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Statistical analysis. Data obtained was compared across groups then analyzed using
a paired Student t-test or one-way ANOVA with a Tukey post-hoc test; differences between
means were considered statistically significant at a value of p ≤ 0.05. Data are presented are
a combination of 2-3 experimental repeats. Each experiment incorporated 8-10 mice per
group.
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Results

Oral administration of recombinant human lactoferrin alleviates pulmonary inflammation
post Mtb infection.
Previous studies using bovine derived lactoferrin given in drinking water
demonstrated that continuous-access oral delivery during Mycobacterium tuberculosis
infection could reduce inflammation-related primary granulomatous pathology in mice [98].
A defined protocol was adopted to determine if recombinant human lactoferrin (rHLF)
would initiate a similar protective response (Figure 9). Mice were aerosol infected with Mtb,
strain Erdman, and rHLF was given by oral gavage beginning either prior to (prophylactic), or
post (therapeutic) expected initiation of granulomatous responses. Histological assessment
(Figure 8 and Figure 11) revealed marked reduction of pulmonary inflammation in both the
prophylactic and therapeutic rHLF treated groups, in a similar manner to that previously
reported with the bovine LF treatment. Specifically, the rHLF treatments demonstrated
reduced complexity of granulomatous responses, smaller foci of inflammation, with less
cellular accumulation and density in areas of inflammation. Quantitative measurement of
inflammation confirmed histological reduction in pathology due to the rHLF treatments.
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Figure 11. Lactoferrin treatment reduces pulmonary inflammation post infectious
challenge with Mtb. Figure contains identical histographs from Figure 8 for text discussion.
Lungs from Mtb infected mice were assessed at day 28 post aerosol infection (A) and
compared to animals given rHLF in the prophylactic group (B) or therapeutic group (C).
Histologic assessment revealed primary granulomatous response with monocytic cell
infiltration, dense cellular foci, and occluded vascular regions in control infected mice. Both
prophylactic and therapeutic rHLF treatment reduced inflammatory response resulting in
modest inflammatory foci and reduced pathological damage to lung tissue. Hematoxylin
and eosin stained histographs represent formalin fixed lung sections at 10x magnification
obtained from repeated studies with 8 to 10 mice in each group; study representative of
repeat experiments.
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Whole right lobes of mouse lung were collected at 4 weeks post infections and
processed for quantitative assessment of primary granulomatous response. Serial sections
of H&E-stained tissue sections were high resolution scanned to assess area occupied by
inflammation (Figure 12). The Mtb infected group had the largest occluded regions, with
24.79% ± 4.2% relative area occupied by inflammatory response. Both lactoferrin treatment
modalities resulted in reduction of pathology. The prophylactic treatment resulted in
reduction of granuloma area to 21.42% ± 4.1% of lung sections observed, while the
therapeutic treatment significantly reduced occupied space to 17.36% ± 4.9% (p<0.001). Of
interest, there was no change in CFU in the treated group in lung, liver or spleen tissue at 4
weeks post infection (Figure 10 and Figure 12), suggesting that (1) the short-term
administration of lactoferrin did not alter pathogenic burden, and (2) the alteration due to
treatments did not result in significant net dissemination to other tissues.

76

Lung Inflammation Week 4

Area Occupied (%)

40
30

*
20
10
0

M

TB

n
lo
A

e

M

TB

+

H

P)
(
LF
TB
M

+

L
H

T)
(
F

Figure 12. Decreased inflammatory response in lactoferrin treated mice. Mtb infected
mice were assessed by digital analysis for cellularity and inflammation. Area occupied of
pulmonary scanned sections is shown for individual mice, with and without recombinant
HLF treatments. Results represent mean ± standard deviation of the mean. Similar data was
obtained in repeated experiments; 6-10 mice were included per group, per experiment.
Prophylactic treatment, P; therapeutic treatment, T. One Way ANOVA, p≤0.05, Tukey Post
Hoc test for multiple comparisons: p≤0.05 for MTB vs MTB+HLF(T).
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Increased penetration of fluoroquinolone to inflammatory foci after treatment with rHLF.
The altered pathology of less dense granulomatous structures raised the hypothesis
that vascular structure would be maintained in the rHLF treated groups, which could
subsequently result in enhanced penetration of mycobacterial therapeutic agents to within
regions of inflammation. To test this, the naturally fluorescent fluoroquinolone, ofloxacin,
was intravenous administered to mice 30 minutes prior to sacrifice at the 28 days post
infection time point. Figure 13 reveals the penetration patterns of ofloxacin to within
regions of pulmonary granulomatous response. The histologically dense inflammatory
response in the Mtb alone group did not permit penetration of the fluoroquinolone, with
little to no signal entering granulomatous foci. In contrast, both the prophylactic and the
therapeutic rHLF treatment protocols resulted in granulomas that were permissible to
ofloxacin penetration. Assessment of serial sections by high resolution scanning revealed
significant differences between groups (Figure 14). The Mtb alone infected group had a
relative fluorescent distribution of signal 13.76% ± 7.5%, confirming the relative difficulty in
penetration of ofloxacin to within inflammatory regions. For comparison, the relative
fluorescence of normal mouse lung had an average of 90.25% ± 3.5% penetration, reflecting
antibiotic distribution to the lung at 30 minutes post delivery. Of interest, in alignment with
visual observations described above, both rHLF treated groups demonstrated elevated
ofloxacin penetration within granulomas. The prophylactic treatment permitted relative
increases to 21.68% ± 14.1%, and the therapeutic treatment showed significant increase at
47.15% ± 14.9% presence of fluorescent signal. Furthermore, high power observation of
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signal revealed accumulation of ofloxacin correlating with presence of activated foamy
macrophages (Figure 15).

Figure 13. Increased fluoroquinolone penetration to primary granulomas after treatment
with lactoferrin. Lungs from Mtb infected mice alone (left), or rHLF treated prophylactically
(P; middle) or therapeutically (T; right) were assessed for presence of ofloxacin within
granulomatous inflammation. Ofloxacin penetration was primarily excluded from
inflammatory foci in the Mtb infected alone group, while both rHLF treated mice permitted
entry of ofloxacin into regions of pathology. Top panels represent hematoxylin & eosin
(H&E) brightfield stained histographs (40x magnification) with matching fluorescence
captured using multispectral imaging (bottom).
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Figure 14. Relative fluorescence for individual inflammatory foci post lactoferrin
treatment. Quantitative assessment of ofloxacin penetration into granulomas in lactoferrin
treated mice are compared to non-treated infected animals. Individual scans are
represented from at least 8 mice per group; average values and standard deviation
included. Prophylactic treatment, P; therapeutic treatment, T. One Way ANOVA, p≤0.05,
Tukey Post Hoc test for multiple comparisons: *p≤0.001 for MTB vs MTB+(T)HLF and
p≤0.001 for MTB vs Normal.
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Figure 15. Accumulation of ofloxacin signal in activated macrophages in lactoferrin
treated Mtb infected mice. H&E staining of inflammatory foci within rHLF therapeutically
treated mouse lung revealed acute regions of highly activated “foamy” macrophagephenotypic cells. Mutispectral imaging correlates the presence of fluorescence which
overlaps presence of activated cells, located within the focal granulomatous regions.
Representative section, 100x magnification.
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rHLF treatment correlates with retention of endothelial integrity in regions of pulmonary
inflammation.
The Mtb alone infected group demonstrated responses consistent with pulmonary
disruption to alveolar structure and associated vascular tissue. To further examine the
effect of the rHLF treatment on vascular structure, histological sections were stained with
PECAM-1. Granulomas in the Mtb alone group demonstrated collapsed alveoli with central
accumulation of immune cells in regions that disrupt blood distribution (Figure 16). Central
foci in these mice were devoid of staining, representing reduced vascularization to regions
where organisms are expected to reside. In contrast, the rHLF treated mice demonstrated
retention of vascularized structures within areas of inflammation, which also corresponded
in matched sections to regions demonstrating ofloxacin penetration.
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Figure 16. Retention of vascularized structures within regions of inflammation in
lactoferrin treated Mtb-infected mice. Serial sections compared presence of maintained
vascular structure within inflammatory foci in Mtb infected mice (left side) or in Mtb
infected mice treated therapeutically with rHLF (right side). Fluorescence patterns obtained
using multispectral imaging (top panels) were compared with serial lung sections that were
immunohistochemically stained for PECAM-1 to identify vascular endothelial populations
within inflammatory foci (bottom panels). VE, vascular endothelium; AE, alveolar capillary
endothelium; A, alveolus.
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Altered localization of M1/M2-like macrophages in primary granulomas following rHLF
treatment.
Recent reports demonstrated altered distribution of macrophage populations within
primary granulomas, which may dictate pathological outcomes [259]. Therefore, sections
were also immunohistochemically stained for general M1-like and M2-like antigens. Figure
17 depicts immunohistochemical staining for the M1-like marker CD38 and for the M2-like
marker CD206. The non-treated Mtb infected lungs revealed a concentrated pattern of
staining demonstrating high presence of both M1-like and M2-like macrophages, primarily
cuffing vascular regions surrounding regions of inflammation. Limited numbers of M2-like
cells were visible (diffuse staining) within the granuloma itself. In contrast, the rHLF treated
mice exhibited primarily only M2-like macrophages, which were evenly distributed
throughout the primary granulomatous pathology; M1-like cells were not readily apparent.
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Figure 17. Altered localization of M1-like and M2-like populations following lactoferrin
treatment of Mtb infected mice. Serial sections of formalin fixed lung tissue were reacted
with antibody to CD38 (top) or CD206 (bottom), for either Mtb alone (left side) or Mtb
infected mice treated therapeutically with rHLF (right side). Mtb alone infected mice
demonstrate accumulation of both M1- and M2-like phenotypic cells in a cuffing pattern
surrounding blood vessels adjacent to granulomatous inflammation. A different pattern
appears in the rHLF treated group, with minimal presence of M1-like phenotype and a
primarily diffuse distribution of M2-like cells throughout the inflammatory foci.
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Summary of Chapter

Infection with Mtb results in the primary formation of a densely packed
inflammatory foci that limits entry of therapeutic agents into pulmonary sites where
organisms reside. No current therapeutic regimens exist that modulate host immune
responses to permit increased drug penetration to regions of pathological damage during
tuberculosis disease. Lactoferrin is a natural iron-binding protein previously demonstrated
to modulate inflammation and granuloma cohesiveness, while maintaining control of
pathogenic burden. Studies were designed to continue examination of recombinant human
lactoferrin (rHLF) to modulate histological progression of Mtb-induced pathology. The rHLF
was oral administered prophylactically, at times corresponding to initiation of primary
granulomatous response, or as a therapeutic intervention during granuloma maintenance.
Treatment with rHLF demonstrated significant reduction in size of primary inflammatory
foci following Mtb challenge, and permitted penetration of ofloxacin fluoroquinolone
therapeutic to sites of pathological disruption where activated (foamy) macrophages reside.
Increased drug penetration was accompanied by retention of endothelial cell integrity
within pulmonary parenchyma. Finally, preliminary examination by immunohistochemistry
revealed altered patterns of M1-like and M2-like phenotypic cell localization post infectious
challenge, with increased presence of M2-like markers found evenly distributed throughout
regions of pulmonary inflammatory foci in rHLF treated mice.
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CHAPTER 5: DISCUSSION AND FUTURE DIRECTIONS

Discussion

The research for host-directed therapeutics is intended to increase the success of
Tuberculosis treatment by affecting the immune response to modulate its function towards
a protective response. Immune-based therapeutics is an intervention to orchestrate the
reduction of non-productive inflammation in a way that redirects the immune response
during infection in a manner that benefits the host. In contrast, immunomodulation is
intended to lie within the framework of harmonizing with anti-TB treatment regimens
against drug susceptible- and drug resistant-TB to improve the entire recovery process and
promote absolute cure. Host-directed therapeutics are, therefore, considered necessary to
reach the goals set by the World Health Organization (WHO) to end TB by 2035. Repurposed
compounds and molecules are increasingly being used in human clinical trials investigating
new host-directed therapeutics [260]. In this regard, lactoferrin, a well-known immune
modulator that has been investigated in many clinical trials for protection and prevention of
infections, came to be a promising candidate. In this thesis, lactoferrin is used as an
immunomodulating therapeutic, given orally during the innate immune response, to both
lessen the development of disease pathology and to improve drug distribution in
granulomas. Overall, this strategy would benefit host pathology resulting in limiting the
growth and spread of Mtb.
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This thesis represents the first report that recombinant human lactoferrin can
modulate the granulomatous response during primary Mtb infection in mice, in a manner
nearly identical to that reported for bovine lactoferrin [98]. The results presented indicate
utility for human lactoferrin administered orally as a therapeutic approach to limit
pathological damage during primary granuloma development. The intervention led to
increased penetration of ofloxacin to regions where Mtb typically reside. The observations
in these thesis studies verified effects in both non-infectious, examining induced
granulomas using purified mycobacterial mycolic acid TDM [78], and primary TB model,
delivered via aerosol infection, where administration of rHLF achieved inflammation
reduction in the lungs and greater ofloxacin distribution throughout granulomatous
structures after treatment.

Lactoferrin-induced modulation in inflammatory response within mycobacterialinduced granulomas is likely the result of two concurrent events; that of significantly less
proinflammatory cytokine production and reduction in recruited M1-like macrophages [78].
Alveolar macrophages uptake Mtb during primary infection and become essentially the key
cell phenotype to recruit and activate additional naïve macrophages to the sites of
infection [34, 140]. Classically activated macrophages polarize to the M1-like phenotype and
exhibit functional phagocytosis and killing of bacteria. As a pathological by-product, they
initiate immune cell recruitment via secreted proinflammatory cytokines which aid in the
establishment of granulomatous tissue structures. Temporally, the subsequent recruitment
and introduction of M2-like macrophages allows immune modification of the aggressive
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inflammatory response, permitting an immunological “brake” to an overwhelming
pathological response [21, 147, 197, 198, 261]. While further investigation is required, it is
theorized that a balance in the presence of macrophage phenotypes within the
granulomatous structures is essential to control pathological mediators by innate immune
cells [66], which is critical to regulation of IL-1β (T cell activation and migration) [262] and
TNF- (vasodilatation and leukocyte adhesion to epithelium) [263] necessary as a response
to control bacterial growth.

A major observation of this study was that the second-line mycobacterial
therapeutic fluoroquinolone was able to penetrate within inflammatory foci. Similar to
results using the TDM non-infectious model of pathology, significant amount of ofloxacin
was found within granulomas following treatment with human lactoferrin, especially, but
not limited to, regions of reduced inflammation. Concurrently, the lactoferrin-treated mice
exhibited granulomatous responses with maintained vascular structures and open alveolar
spaces. Acute inflammation and reactivity during Mtb infection occurs primarily peripheral
to vascular regions, coinciding with destruction in continuity of endothelial lined blood
vessels [258, 264]. In the experiments presented in this thesis, lactoferrin treatment
allowed greater regions of lung tissue, and alveolar spaces, to remain unobstructed, as
evident using the PECAM-1 endothelial surface marker. This coincided with observational
retention of blood vessels within regions of pathology. The lessened pathological damage in
the lactoferrin treated animals, along with significant maintenance of vascular architecture,
likely permitted ofloxacin transport inside of granulomas, as evident by the drug’s
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fluorescent signal observed within and around the endothelial-lined vessels. This raises the
hypothesis for use of lactoferrin as a safe adjuvant molecule to increase delivery of standard
Mtb therapeutics. This may also have the potential to reduce overall treatment times, limit
drug sensitivity development, and reduce antibiotic side effects in patients undergoing
treatment.

A major concern with current host-directed therapy is the increase of bacterial
dissemination during treatment, such as seen when TNF-αblockers are used [88-91]. It is
crucial that the role of established granulomas is maintained throughout the antimycobacterial treatment; specifically, the activation of recruited immune cells must be
maintained to limit organism spread to other tissues. The observations in this thesis
demonstrated no increase in lung CFUs in the treated group and no change in levels of
detected organisms in liver and spleen. Such observations align with previous studies using
bovine lactoferrin in a similar Mtb infectious model [98]. This shows potential therapeutic
application of recombinant human lactoferrin to reduce pathological damage due to
infection. And it does so without the major side effect of other host-directed therapies,
including the compromising of Mtb confinement at the site of initial inflammation.

Lactoferrin immune-modulating effects in the Mtb infectious model are consistent
with other infectious models reported [115, 265, 266]. And its utility as a host-directed
therapeutic has been demonstrated in other diseases where host inflammation plays a key
role in pathology development [115, 267]. Lactoferrin was used successfully in clinical trials
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a prophylactic to prevent development of enterocolitis and sepsis [107, 268, 269]. In a
similar manner, the prophylactic administration presented here was done prior to the
establishment of granulomatous pathology. However, significant results were surprisingly
identified when lactoferrin was given as a therapeutic at day 21 post infection at a time
after granulomas have initiated in the lungs. Of clinical importance, when lactoferrin was
used therapeutically it both decreased overall lung inflammation and increased ofloxacin
distribution in granulomas.

The results in this thesis also brought to light the underlying functional activity of a
relatively novel recombinant human lactoferrin. Most previous studies investigating the
immune-modulating effects of lactoferrin used bovine lactoferrin due to its considerable
availability and affordable pricing as a byproduct of cow milk. Though experiment and
clinical trials on bovine lactoferrin immunomodulating effects show great potential as a
therapeutic component, there is roughly a 30% difference in sequence identity between
bovine and human lactoferrin [270]. In terms of amino acid composition, there are 696
amino acids in bovine lactoferrin compared with 691 amino acids in the human molecule
[271, 272]. Since there are differences in their structure, though not major, there remains a
gap where species compatibility might affect optimalization of modulating properties
against human diseases, which is rarely observed and explored. In these sets of
experiments, the consistent immunomodulating effects in the treated groups, in both TDM
and Mtb models, shed light into this unexplored area. This was achievable due to the novel
production of recombinant human lactoferrin using a stable Chinese hamster ovary cell line
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(CHO) that is widely accepted as a leading mammalian platform in pharmaceutical
production [273], thus allowing the use of recombinant human lactoferrin to be much more
affordable and accessible in research. The recombinant human lactoferrin that was used in
these studies possesses human-like glycosylation patterns, sequence identity, and
antibacterial functions that are similar to that found in breast milk derived human
lactoferrin [273].

Mechanistically, lactoferrin can induce dendritic cell activation and maturation,
specifically supporting functions of antigen presenting cell (APC) populations that act as to
bridge innate and adaptive immunity [274-278]. Lactoferrin can directly enhance the
antigen presenting activity and T-cell stimulation function in mycobacterial-infected
macrophages [279]. Lactoferrin can also modulate T-cell activities in multiple ways [115]. In
vitro, T-cell maturation and expression of T-cell ζ-chain, a component of T-cell receptor
(TCR) complex involved in receptor signaling pathways, can be increased upon treatment
with lactoferrin [280-282]; T-cell adhesive molecules involved in cell-to-cell contact are also
increased in the presence of lactoferrin [283]. Bovine lactoferrin administered orally
increased IFN- Th1 T-cell responses [284] and NK cell activity in mice [285] likely by
increasing IL-12 and related cytokines [285, 286]. Together, these suggest possible
modulations of T cell activities, combined with enhanced antigen-presenting cell maturation
and macrophage recruitment effects, which theoretically shift the overall outcome of
granulomas to successful containment of pathogens
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The observations using the TDM-induced granuloma model demonstrated that
lactoferrin could lessen the presence of inflammatory mediators post initiation of pathology
[78], as well as preferentially recruit M2-like cells to granulomas [78]. It is reasonable to
infer that similar reductions using human lactoferrin at 4 weeks post Mtb infection would
occur, since TDM is significantly released from mycobacteria [21, 287]. This also suggests an
important mechanistic link between macrophage recruitment and lactoferrin treatment
during Mtb infection, perhaps via the alteration of surface adhesion markers on monocytes
that would permit increased interaction with endothelial cells [288, 289]. However, it
remains unknown if lactoferrin can differentially affect M1-like versus M2-like activities;
such experiments have only been explored on classical M1-like activated monocytes [198,
279]. This suggests a premise that macrophage polarization could occur in the presence of
lactoferrin, perhaps via the reduction of locally produced proinflammatory cytokines [78,
97, 261, 290, 291].

Future Directions

The studies presented here set a foundation to further investigate usage of human
lactoferrin in combination with standard treatments for Mtb infection. Bacterial
dissemination in later time points after infection, and prolonged treatments, should be
studied to understand the full potential of its use as a host-directed therapeutic. It remains
unknown if lactoferrin treatment, when limited to the duration of early innate immune
responses (such as was done in our models), is enough to significantly amplify the
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bactericidal effect of Ofloxacin when given as a standard TB treatment regimen. In reality, it
is not clinically feasible to identify individuals prior to development of pathology and
granuloma formation. Therefore, more experiments are needed to determine the extent of
human lactoferrin on the adaptive immune response when treatments begin after exposure
at the primary granuloma establishment and maintenance stages.

The understanding of how Lactoferrin exerts its immunomodulating effect to the
granulomatous response remains to be explored. The molecule is known to interact with
“danger signal” receptors in addition to the lactoferrin receptor [252], therefore, it is
remains unclear where such interactions happen physically during the granulomatous
response. Future studies are needed to determine if lactoferrin works from within the
granuloma structure as it penetrates the dense inflammatory tissues or indirectly by
interacting with recruited immune cells in blood vessels and normal lung tissue (with
secondary effects culminating in altered granuloma structure). In the non-infectious model
where macrophages are responsible for the majority of inflammatory response, it is unclear
how lactoferrin modulated the macrophage immune response. It has been established that
bovine lactoferrin improved antigen-presentation in BCG infected bone marrow-derived
macrophages by increasing surface expression of Class II (I-Ab) [120]. Therefore, more
investigation is needed to confirm such effect, as well as other unknown changes in
phenotype and intercellular signaling, in macrophages caused by lactoferrin during the
primary immune response to Mtb infection.
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Though a significant modulation of granulomatous response was achieved by giving
lactoferrin orally, further investigation is needed for a thorough analysis of how much
recombinant human lactoferrin was absorbed through the gut, and whether its intact
structure and glycosylation presence within the circulating blood and lung tissue survives
degradation in the digestive system.It is expected that bioavailability is affected by protein
degradation and absorption. Recent studies by Kruzel, et al [292] suggest that up-regulation
of specific genes involved in oxidative stress and inflammation occur after oral delivery.
Future in-depth studies can extend comparisons of efficiency of different delivery methods
when lactoferrin is given as a therapeutic for TB, such as when given orally, deposited on
mucosal surfaces, or injected intravenously. In this study, the modulating effect of
lactoferrin during the establishment of granulomas was investigated, which was not
maintained after 4 weeks of ending lactoferrin treatment (8 weeks post Mtb infection).
Therefore, future studies using lactoferrin in a longer term and more persistent manner is
needed to discover the extent of its effect, long-term consequences, and the appropriate
exposure to lactoferrin for optimized treatments.

Overall, a role for clinical utility of human lactoferrin to modify the aggressive
immune function during primary Mtb infection may exist, which would allow greater
efficacy of treatments. In turn, this would potentially reduce standard treatment duration,
antibiotic side effects, and overall pathological damage in patients.
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